





HOSPITAL OUTPATIENT CODING AND BILLING INFORMATION SHEET FOR NEULASTA® ONPRO®, NEULASTA®, AND NEUPOGEN®

Contact Amgen Assist 360[™] for reimbursement and access resources at 1-888-4ASSIST or www.AmgenAssist360.com

Neulasta[®] (pegfilgrastim) is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.¹


Neulasta[®] is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.¹

Neulasta® Onpro® kit, which includes: the same Neulasta[®] as in the Prefilled Syringe with a different delivery option¹



- Must be prepared and applied by a healthcare provider on the same day as chemotherapy¹
- The prefilled syringe co-packaged in the Neulasta® Onpro[®] kit must only be used with the On-body Injector for Neulasta®
- Designed to deliver a full dose of Neulasta[®] approximately 27 hours after its activation¹
- As per the label, a healthcare provider may initiate administration with the On-body Injector for Neulasta® (also referred to as the "On-body Injector") on the same day as the administration of cytotoxic chemotherapy, and the On-body Injector is designed to deliver pegfilgrastim approximately 27 hours after application¹

Apply today, deliver* Neulasta[®] tomorrow¹



* The On-body Injector for Neulasta® is designed to deliver Neulasta® approximately 27 hours after activation

Important Safety Information

Contraindication

• Neulasta[®] or NEUPOGEN[®] are contraindicated in patients with a history of serious allergic reactions to human granulocyte colony-stimulating factors (G-CSFs), such as pegfilgrastim or filgrastim

Please see additional Important Safety Information on pages 10-11.



Neulasta[®] delivered via the On-body Injector vs Neulasta[®] delivered via the manual use Neulasta® Prefilled Syringe

SELECT ATTRIBUTES

Active Ingredient¹

Indication¹

Route of Administration¹

Deliverable Dose¹

WAC^{3,4}

J-code^{5,}*

How Delivered and CPT Code^{1,6,}

NDC Number^{1,*}

* See next page for coding and billing information sheet for Neulasta®. NDC = National Drug Code; WAC = wholesale acquisition cost.

On-body Injector for Neulasta®

A missed dose could occur due to an On-body Injector for Neulasta[®] failure or leakage. If the patient misses a dose, a new dose should be administered by single prefilled syringe for manual use, as soon as possible after detection.

The On-body Injector is backed by 24/7 telephone support and a full return policy. Call **1-844-MYNEULASTA** at any time for assistance or answers to product-related questions.

Important Safety Information

Splenic Rupture

Please see additional Important Safety Information on pages 10-11.

	SAME	DIFFERENT
	\checkmark	
*		\checkmark
		\checkmark

 Splenic rupture, including fatal cases, can occur following the administration of Neulasta[®] and NEUPOGEN[®] • Evaluate for an enlarged or ruptured spleen in patients who report left upper abdominal or shoulder pain



Hospital Outpatient – Billing Information Sheet for the Neulasta® Onpro® kit

Item	Revenue Code ^{7,8}	Coding Information (HCPCS ⁵ /CPT ⁶ /ICD-10-CM)	Notes
Neulasta® Onpro® kit	Medicare: 0636, drugs	J2506 , injection, pegfilgrastim, excludes biosimilar, 0.5 mg	Neulasta [®] is supplied as a 6 mg deliverable dose. ¹
	requiring detailed coding ⁹		Effective Jan 1, 2022, the HCPCS has changed from J2505 to J2506,
	Other Payers: 0250, general pharmacy;		injection, pegfilgrastim, excludes biosimilar, 0.5 mg.
	OR 0636, if required by a given payer ⁹		55513-0192-01 is the NDC number (in the 11-digit format) for Neulasta [®] Onpro [®] kit. ¹
			Healthcare providers should ensure Service Units (Box 46) are appropriately billed.
Administration of the On-body Injector	Appropriate revenue code for the cost center in which the service	96377, application of on-body injector (includes cannula insertion) for timed subcutaneous injection	Healthcare providers can initiate administration with the On-body Injector on the same day as the administration of chemotherapy. ^{1,*}
	is performed		See payer guidelines for specific coding requirements.
Diagnosis/ Condition	N/A	Appropriate ICD-10-CM diagnosis code(s) for patient condition.	Allowable diagnosis codes may vary by payer.

*As long as Neulasta® is not delivered between 14 days before and 24 hours after administration of cytotoxic chemotherapy.


CPT = Current Procedural Terminology; HCPCS = Healthcare Common Procedure Coding System; ICD-10-CM = International Classification of Diseases, Tenth Revision, Clinical Modification

The information provided in this Coding and Billing Information document is of a general nature and for informational purposes only and is not intended to be a comprehensive list nor instructive. Coding and coverage policies change periodically and often without warning. The responsibility to determine coverage and reimbursement parameters, and appropriate coding for a particular patient and/or procedure, is always the responsibility of the provider or physician. The information provided in this section should in no way be considered a guarantee of coverage or reimbursement for any product or service.

Contact Amgen Assist 360[™] for reimbursement and access resources at 1-888-4ASSIST or www.AmgenAssist360.com



The CMS 1450 for Hospital Outpatient – the Neulasta[®] Onpro[®] kit



This sample form is intended as a reference for coding and billing for product and associated services. It is not intended to be a directive, nor does the use of the recommended codes guarantee reimbursement. Physicians and staff may deem other codes or policies more appropriate. Providers should select the coding options that most accurately reflect their internal system guidelines, payer requirements, practice patterns, and the services rendered. Providers are responsible for ensuring the accuracy and validity of all billing and claims for appropriate reimbursement.

					iistiatio							
				3a PA CNTL	т. #						4 T) OF	/PE BILL
				b. ME REC.	D. #							
					TAX NO.	6 STA		OVERS PERIO		7		
						E Di	2101	THROUG	211	1		
	12	2	Main	S+r	eet, An	vtown	Anv	state	12	345		
ľ	1 44		PICLI	DUL	ccc, m					.545		
			CONDITIC	NICODEC		0		d ACEET 20			е	
2	0	21	22	N CODES	24 25	26 27	28 5	ACDT 30 TATE				
			00000000	SPA						1.07		
E (BO)	〈 4	5)		SERVICE	UNITS (I	30X 4	6)				
	vice.	Foi			Report uni	ts of servi	ce for	Neulast	a®			Ĩ
)n-bod		in accordar						DES	
											T	
					(i.e., 12 ser			ng). Net	llast	d-		
ар	pliec				dose is 6 m	ng, per la	oel.					
	с											-
	d				¥:							
DE	u u		45 SERV. DAT	re l	16 SERV. UNITS	47 TOTAL CH	40050		1 001	ERED CHAP	0050	49
DE						47 TOTAL OF			111-000	EHED CHAP	1665	49
			MMDI		12		XXX					
			MMDI	YYC	1		XXX	XX				
				I							:	
DD	E (B	O)	(44)		PR	OCEDU	RE CO	DE (BC)X 4	4)		
bd						lated ad						
						e CPT® co						
nila	ır, 0.5	5 m	g.		per	formed, s	such a	s 96377	', ap	oplicat	tion	
ah	le d	isca	arded		on-	body inje	ector (includes				ertion
					for	timed su	bcuta	neous ir	niec	tion.		
			ted on									
viti	1 J25	06	and th	ie		te: Healti						
					adr			h the Oi	n-bc	ody Inj	iecto	
	the	IG	modif		on			s the ao			ion	
	n Me											
ມບ					Of a	chemothe	ranv'					
						chemothe						
	nt cl		is to bi		*A:	s long as						
tely	nt cl / pay	aim ⁄abl	ls to bil le drug		*A:							s afte
tely	nt cl / pay	aim ⁄abl	is to bi		*As be	s long as		sta® is n ; before		l 24 h	ours	
tely las	nt cl / pay ta®)	aim /abl acc	is to bil le drug juired		*As be	s long as etween 1		sta® is n ; before		l 24 h	ours	
tely las	nt cl / pay ta®)	aim /abl acc	ls to bil le drug		*As be	s long as etween 1		sta® is n ; before		l 24 h	ours	
tely las	nt cl / pay ta®)	aim /abl acc	is to bil le drug juired		*As be	s long as etween 1		sta® is n ; before		l 24 h	ours	
tely las	nt cl / pay ta®)	aim /abl acc	is to bil le drug juired		*As be	s long as etween 1		sta® is n ; before		l 24 h	ours	
tely las 40I	nt cl / pay ta®) 3 prc	aim /abl acc ogra	is to bil le drug juired	IS	*As be ac	s long as etween 1		sta® is n ; before		l 24 h	ours	
tely las 40I	nt cl. / pay ta®) 3 prc	aim /abl acc ogra	is to bil le drug juired am. ¹¹	IS	*A be ac	s long as etween 1 Iministrat	Neula 4 days tion of	sta® is n ; before		l 24 h	ours	
tely las 401	nt cl / pay ta®) 3 prc	aim /abl acc ogra	is to bil le drug juired	IS	*As be ac	s long as etween 1 Iministrat		sta® is n ; before		l 24 h	ours	
tely las 401	nt cl / pay ta®) 3 prc	aim /abl acc ogra	is to bil le drug juired am. ¹¹	IS	*A be ac	s long as etween 1 Iministrat	Neula 4 days tion of	sta® is n ; before		l 24 h	ours	
tely las 401	nt cl / pay ta®) 3 prc	aim /abl acc ogra	is to bil le drug juired am. ¹¹	IS	*A be ac	s long as etween 1 Iministrat	Neula 4 days tion of	sta® is n ; before		l 24 h	ours	
tely las 401	nt cl / pay ta®) 3 prc	aim /abl acc ogra	is to bil le drug juired am. ¹¹	IS	*A be ac	s long as etween 1 Iministrat	56 NPI	sta® is n ; before		l 24 h	ours	
tely las 401	nt cl / pay ta®) 3 prc	aim /abl acc ogra	is to bil le drug juired am. ¹¹	S ENTS	*A be ac	s long as etween 1 Iministrat	56 NPI 57 OTHER PRV ID	sta® is n ; before f cytotoo	anc kic c	l 24 h	ours	
tely las 401	nt cl / pay ta®) 3 prc	aim /abl acc ogra	is to bil le drug juired am. ¹¹	S ENTS	*A be ac	s long as etween 1 Iministrat	56 NPI 57 OTHER PRV ID	sta® is n ; before	anc kic c	l 24 h	ours	
tely las 401	nt cl / pay ta®) 3 prc	aim /abl acc ogra	is to bil le drug juired am. ¹¹	S ENTS	*A be ac	s long as etween 1 Iministrat	56 NPI 57 OTHER PRV ID	sta® is n ; before f cytotoo	anc kic c	l 24 h	ours	
tely las 401	nt cl / pay ta®) 3 prc	aim /abl acc ogra	is to bil le drug juired am. ¹¹	S ENTS	*A be ac	s long as etween 1 Iministrat	56 NPI 57 OTHER PRV ID	sta® is n ; before f cytotoo	anc kic c	l 24 h	ours	
tely las 401	nt cl / pay ta®) 3 prc	aim /abl acc ogra	is to bil le drug juired am. ¹¹	S ENTS	*A be ac	s long as etween 1 Iministrat	56 NPI 57 OTHER PRV ID	sta® is n ; before f cytotoo	anc kic c	l 24 h	ours	
tely las 401	nt cl / pay ta®) 3 prc	aim vabl acc ogra 54 Pl	is to bil le drug juired am. ¹¹	S ENTS	*A be ac	s long as etween 1 Iministrat	56 NPI 57 OTHER PRV ID 62 INSU	sta® is n ; before f cytotoo	anc kic c	l 24 h	ours	
tely las 401	nt cl. / pay ta®) 3 prc	aim vabl acc ogra 54 Pl	is to bil le drug juired am. ¹¹	S ENTS	*A be ac	s long as stween 1 Iministrat	56 NPI 57 OTHER PRV ID 62 INSU	sta® is n ; before f cytotoo	anc kic c	l 24 h	ours	
tely las 401	nt cl. / pay ta®) 3 prc	aim vabl acc ogra 54 Pl	is to bil le drug juired am. ¹¹	S ENTS	*A be ac	s long as stween 1 Iministrat	56 NPI 57 OTHER PRV ID 62 INSU	sta® is n ; before f cytotoo	anc kic c	l 24 h	ours	
tely las 401	nt cl. / pay ta®) 3 prc	aim vabl acc ogra 54 Pl	is to bil le drug juired am. ¹¹	S ENTS	*A be ac	s long as stween 1 Iministrat	56 NPI 57 OTHER PRV ID 62 INSU	sta® is n ; before f cytotoo	anc kic c	1 24 h	ours	
tely las 401	nt cl. / pay ta®) 3 prc	aim vabl acc ogra 54 Pl	is to bil le drug juired am. ¹¹	S ENTS	*A be ac	s long as stween 1 Iministrat	56 NPI 57 OTHER PRV ID 62 INSU	sta® is n ; before f cytotoo	anc kic c	I 24 h hema	ours	
tely las 401	nt cl. / pay ta®) 3 prc	aim vabl acc ogra 54 Pl	is to bil le drug juired am. ¹¹	S ENTS	*A be ac	s long as stween 1 Iministrat	56 NPI 57 OTHER PRV ID 62 INSU	sta® is n ; before f cytotoo	anc kic c	I 24 h hema	ours	
tely las 401	nt cl. / pay ta®) 3 prc	aim vabl acc ogra 54 Pl	is to bil le drug juired am. ¹¹	S ENTS	*A be ac	s long as stween 1 Iministrat	56 NPI 57 OTHER PRV ID 62 INSU	sta® is n ; before f cytotoo	anc kic c	I 24 h hema	ours	
tely las 401	nt cl. / pay ta®) 3 prc	aim vabl acc ogra 54 Pl	IS to bille e drug juired am. ¹¹	S ENTS	*A be ac	s long as stween 1 Iministrat	56 NPI 57 OTHER PRV ID 62 INSU	sta® is n ; before f cytotoo	anc kic c	I 24 h hema	ours	
	nt cl. (/ pay ta®)) 3 pro	aim vabl acc ogra 54 Pl	s to bil e drug juired am. ¹¹	IS	TOTALS 55 EST, AMOUN JP NAME 65 E	s long as stween 1 Iministrat T DUE EMPLOYER NA	56 NPI 57 OTHER PRV ID 62 INSU	sta® is n before f cytotos		I 24 h hema	ours	
	nt cl. / pay ta®) B prc DAT/ S3 ASGL BEN. IUMBER	aim vabl acc ogra 54 Pl	RIOR PAYME	IS	TOTALS	s long as stween 1 Iministrat T DUE EMPLOYER NA	56 NPI 57 OTHER PRV ID 62 INSU	sta® is n before f cytotos RANCE GROL		I 24 h hema	ours	
	nt cl. / pay ta®) 3 pro	aim vabl acc ogra 54 Pl	RIOR PAYME	IS	TOTALS	s long as stween 1 Iministrat T DUE EMPLOYER NA	56 NPI 57 OTHER PRV ID 62 INSU	sta® is n before f cytotos		I 24 h hema	ours	
	nt cl. / pay ta®) 3 pro	aim vabl acc ogra 54 Pl	RIOR PAYME	S ENTS 61 GROU 61 GROU 61 LAST	TOTALS	s long as stween 1 dministration T DUE EMPLOYER NA G P b	56 NPI 57 OTHER PRV ID 62 INSU	sta® is n before f cytotos RANCE GROL		I 24 h hema	ours	
	nt cl. (/ pay ta®)) 3 pro	aim vabl acc ogra 54 Pl	RIOR PAYME	S ENTS 61 GROU 61 GROU 61 LAST	TOTALS	s long as stween 1 dministration T DUE EMPLOYER NA G P b	56 NPI 57 OTHER PRV ID 62 INSU	sta® is n before f cytotox RANCE GROL		I 24 h hema	ours	
	nt cl. / pay ta®) 3 pro	aim vabl acc ogra 54 Pl	RIOR PAYME	ENTS	TOTALS 55 EST, AMOUN 55 EST, AMOUN 55 EST, AMOUN 56 EST, AMOUN 57 EST, AMOUN 58 EST, AMOUN 59 EST, A	s long as stween 1 dministration T DUE EMPLOYER NA G P b	56 NPI 57 OTHER PRV ID 62 INSU	RANCE GROL		I 24 h hema	ours	
	nt cl. / pay ta®) 3 pro	aim vabl acc ogra 54 Pl	RIOR PAYME	ENTS 61 GROU 76 A ⁻ 1457 77 O 1457 78 O	TOTALS 55 EST, AMOUN 55 EST, AMOUN	s long as stween 1 dministration T DUE EMPLOYER NA G P b	56 NPI 57 OTHER PRV ID 62 INSU	RANCE GROL		I 24 h hema	ours	
	nt cl. / pay ta®) 3 pro	aim vabl acc ogra 54 Pl	RIOR PAYME	61 GRO	TOTALS TOTALS SSEST, AMOUN	s long as tween 1 Iministrat move EMPLOYER NA G P b	56 NPI 57 OTHER PRV ID 62 INSU	RANCE GROL		I 24 h hema	ours	
	nt cl. / pay ta®) 3 pro	aim vabl acc ogra 54 Pl	RIOR PAYME	61 GRO	TOTALS 55 EST, AMOUN 55 EST, AMOUN	s long as tween 1 Iministrat move EMPLOYER NA G P b	56 NPI 57 OTHER PRV ID 62 INSU	RANCE GROL		I 24 h hema	ours	
	nt cl. / pay ta®) 3 pro	aim vabl acc ogra 54 Pl	RIOR PAYME	S S S S S S S S S S S S S S	*A: be ac TOTALS ss ss \$55 EST, AMOUN ss ss JP NAME ss ss PRATING NPI ss PRATING NPI ss THER NPI ss	s long as tween 1 dministrat T DUE EMPLOYER NA G P b	56 NPI 57 0THER PRV ID 62 INSU	RANCE GROL		8 8		



Hospital Outpatient – Billing Information Sheet for the **Neulasta® Prefilled Syringe**

Item	Revenue Code ^{7,8}	Coding Information (HCPCS ⁵ /CPT ⁶ /ICD-10-CM)	Notes
Neulasta [®] Prefilled Syringe	Medicare: 0636, drugs	J2506 , injection, pegfilgrastim, excludes biosimilar, 0.5 mg	Neulasta [®] is supplied as a 6 mg deliverable dose. ¹
for Manual Injection	requiring detailed coding ⁹		Effective Jan 1, 2022, the HCPCS has changed from J2505 to J2506, injection, pegfilgrastim, excludes biosimilar, 0.5 mg.
	Other Payers: 0250, general pharmacy; OR 0636, if required by a		55513-0190-01 is the NDC number (in the 11-digit format) for the Neulasta [®] prefilled syringe for manual injection. ¹
	given payer ⁹		Healthcare providers should ensure Service Units (Box 46) are appropriately billed.
Administration of Neulasta [®] Prefilled Syringe for Manual Injection	Appropriate revenue code for the cost center in which the service is performed	96372, therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular	
Diagnosis/ Condition	N/A	Appropriate ICD-10-CM diagnosis code(s) for patient condition.	Allowable diagnosis codes may vary by payer.

The information provided in this Coding and Billing Information document is of a general nature and for informational purposes only and is not intended to be a comprehensive list nor instructive. Coding and coverage policies change periodically and often without warning. The responsibility to determine coverage and reimbursement parameters, and appropriate coding for a particular patient and/or procedure, is always the responsibility of the provider or physician. The information provided in this section should in no way be considered a guarantee of coverage or reimbursement for any product or service.

Important Safety Information

Acute Respiratory Distress Syndrome (ARDS)


- ARDS has occurred in patients receiving Neulasta[®] and NEUPOGEN[®]
- Evaluate patients who develop a fever and lung infiltrates or respiratory distress after receiving Neulasta® or NEUPOGEN®
- Discontinue Neulasta[®] or NEUPOGEN[®] in patients with ARDS

Please see additional Important Safety Information on pages 10-11.

Contact Amgen Assist 360[™] for reimbursement and access resources at 1-888-4ASSIST or www.AmgenAssist360.com



The CMS 1450 for Hospital Outpatient – the Neulasta[®] Prefilled Syringe



This sample form is intended as a reference for coding and billing for product and associated services. It is not intended to be a directive, nor does the use of the recommended codes guarantee reimbursement. Physicians and staff may deem other codes or policies more appropriate. Providers should select the coding options that most accurately reflect their internal system guidelines, payer requirements, practice patterns, and the services rendered. Providers are responsible for ensuring the accuracy and validity of all billing and claims for appropriate reimbursement.

b. MED. REC. # 6 STATEMENT COVERS PERIOD

4 TYPE OF BILL

		01 ED. 170(110)		FRC	M	THROU	3H		
a 123	Main S	Street,	Anvt	own,	Anv	state	1234	5	
110				c		d		е	
20 21	CONDITION C	CODES 3 24 25	5 26	27	28 29 28 S	ACDT 30 TATE			
(BOX 45)		ICE UN						
rvice. For						Neulast			
						de desci			
or manua						ng). Neu	ulasta®	ODES	
ninistered		dose I	s 6 mg,	per lac	el.				
b									
с									
d		¥							
DE	45 SERV. DATE	46 SERV. UN		47 TOTAL CH			ON-COVERED	CHARGES	49
	MMDD	(Y 1	.2		XXX	XX			
	MMDD	(Y	1		XXX	XX			
		_			-				
DE (BO)	(44)		PROC	EDUB	Ε CO	DE (BC)X 44)		
de)						tratio		dure	
	octim					resentir		eaure	
, pegfilgra ilar, 0.5 m						ed, suc		372	
						ylactic,			
ble, disca						ubstanc			
be repor ith J2506						tramus			
111 J2 500	and the								
le, the JG									
on Medi									
ient claim ely payabl		or							
asta®) acc									
0B progra									
ob piogra	ai i i .								
N DATE		TOTAL	.s 📂						
IEL 53 ASG BEN. 54 F	PRIOR PAYMENT	S 55 EST.	AMOUNT DU	JE	56 NPI				
					57				
					OTHER				
					PRV ID				
	6	1 GROUP NAME			62 INSU	RANCE GROU	JP NO.		
			05 51						
OL NUMBER			65 EMF	PLOYER NAM	IC.				
		E		G		Ы	68		
		6		Ď		0			
S	72	2		-		C I	73		
EDURE	75 ECI	76 ATTENDING	NPI	-	I	QUAL	-		
DATE	1	LAST				FIRST			
EDURE DATE		77 OPERATING	NPI			QUAL			
DATE	1	LAST				FIRST			
		78 OTHER	NPI			QUAL			
		LAST				FIRST			
		79 OTHER	NPI			QUAL			
		LAST				FIRST			
National Uniform		THE CERTIFICAT	10NS ON TH	E REVERSE	APPLY TC	THIS BILL A	ND ARE MAD	DE A PART H	IEREOF



Hospital Outpatient – Billing Information Sheet for NEUPOGEN®

NEUPOGEN[®] (filgrastim) is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever.¹²

ltem	Revenue Code ^{7,8}	Coding Information (HCPCS ⁵ /CPT ⁶ /ICD-10-CM)	Notes
NEUPOGEN®	Medicare: 0636, drugs requiring detailed coding ⁹	J1442, injection, filgrastim (G-CSF), 1 mcg	The NDC numbers for NEUPOGEN [®] , in the 11-digit format, are as follows: ¹² - 300-mcg vial: 55513-0530-10 - 300-mcg prefilled syringe: 55513-0924-10 - 480-mcg vial: 55513-0546-10
	Other Payers: 0250, general pharmacy; OR 0636, if required by a given payer ⁹		- 480-mcg prefilled syringe: 55513-0209-10
Administration	Appropriate revenue code for the cost center in which the service is performed	96372, therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular	
Diagnosis/ Condition	N/A	Appropriate ICD-10-CM diagnosis code(s) for patient condition.	Allowable diagnosis codes may vary by payer.

Important Safety Information

Serious Allergic Reactions

- Serious allergic reactions, including anaphylaxis can occur in patients receiving Neulasta® and NEUPOGEN®
- Provide symptomatic treatment for allergic reactions
- Majority of events occurred upon initial exposure and can recur within days after discontinuation of initial anti-allergic treatment
- Permanently discontinue Neulasta® or NEUPOGEN® in patients with serious allergic reactions

Please see additional Important Safety Information on pages 10-11.

Contact Amgen Assist 360[™] for reimbursement and access resources at 1-888-4ASSIST or www.AmgenAssist360.com



The CMS 1450 for Hospital Outpatient – NEUPOGEN®

Sample UB		5 1450)	Fo	rm –	Hos	pital O	I
Anytown H 100 Main Anytown, A	Street	01010		2			
8 PATIENT NAME	^a Smith,	Jane			-	ADDRESS	
0 BIRTHDATE	11 SEX 12 DATE	ADMISSION 13 HR 14 T	YPE 15	SBC 16 DH	b R 17 STAT	18 19	_
1 OCCURRENCE			OCCURF		24	CCURRENCE	
CODE DATE	32 OCCURREN CODE DA	TE CODE		DATE	CODE	DATE	
38							
12 REV. CD. 43 DESCRIPT	TON					3 / RATE / HIPPS C	:0
0636 0510 Clin	nic					442 372	
			_				
	CODES (BO ONS (BOX)		D		P	RODUCT roduct (442, inje	J
	lse revenue co		drug	s	N	ote: If ap)
	tailed coding s: Use revenu		50			n a separ	
	rmacy (or 06			y		/hen app ledicare ł	
a given paye						eparately	
	dministration propriate rev					rough th elated a	
for cost cen	ter where ser	vices were				se CPT [®] c	
performed (eg, 0510, clir	11C <i>)</i> .				6372, the pecify sul	
						peeny su	
PAGE	OF					CREATI	0
PAYER NAME	0/		51 HE	ALTH PLAN	ID	5	52 IN
	S CODES (E	ROX 67)	-	59 P. REL	60 INSURE	D'S UNIQUE ID	_
	priate ICD-10						
diagnosis co	ode(s) corresp	onding			64 D		
to patients	diagnosis. All odes may vary		-		04 D(DOUMENT CONT	H
	, ,	51 5					
xxx.x	Α	В		С		D	
9 ADMIT	70 PATIENT	K		, Ľ		71	-
4 PRINCIPAL PRO	REASON DX	OTHER F	ROCEDI	JRE	b.		0
		OTHER	POOTE	IDE			-
OTHER PROC	DATE d.	OTHER F CODE	HOCEDI	JRE DATE	е.	OTHER PRO	pC
D REMARKS			810	a			_
			_	b c			
				d			
3-04 CMS-1450	APPROV	ED OMB NO. 0938	-0997			NUBC	9
							-

This sample form is intended as a reference for coding and billing for product and associated services. It is not intended to be a directive, nor does the use of the recommended codes guarantee reimbursement. Physicians and staff may deem other codes or policies more appropriate. Providers should select the coding options that most accurately reflect their internal system guidelines, payer requirements, practice patterns, and the services rendered. Providers are responsible for ensuring the accuracy and validity of all billing and claims for appropriate reimbursement.

utpatient Administration

Alpallent A	Administrat	1011			
	3a PAT. CNTL #			4 TYPE OF BIL	L
	b.MED. REC.#				
	5 FED. TAX NO.	6 STA FF	TEMENT COVERS F	PERIOD 7 ROUGH	
123 Mai	n Street, A			e 12345	
CON	DITION CODES		c d 29 ACDT 3	0	
20 21 22		E UNITS (
35 OCCUP CODE FROM	DENCE OD			37	_
CODE FROM	Report i	units of serv or J1442 coi			
		of NEUPOGE			
39 CODE		ts for the 30			
a		ts for the 48			
b					
с					
d					
E 45 SERV	DATE 46 SERV. UNITS	47 TOTAL C	HARGES	TOTAL CHARG	ES (BOX 47
MM	DDYY XXX		XXXXX	Report appropria	ate charges
MM	DDYY X		XXXXX	for product used	
				procedures.	
AND PROCE	DURE CODE (E	3OX 44)			e
					6
Code)	(G-CSF), 1 mcg.]
	ded product sho		orted		1
	142 and the JW				
	nodifier should l				1
	ent claims to bill				1
	including NEUP	OGEN®) acq	uired		1
340B program					1
ministratio r					1
	g procedure per				1
	ylactic, or diagno				1
tance or drug)	; subcutaneous o		ular		1
					2
					2
					2
NDATE	TOTALS				2
EL. 53 ASG. D BEN. 54 PRIOR P	YMENTS 55 EST. AM	MOUNT DUE	56 NPI		
			57		4
			OTHER		E
	<u> </u>		PRV ID		d
	61 GROUP NAME		62 INSURANCE 0	AROUP NO.	
					1
U NUMBER		65 EMPLOYER NA	ME		
		So can corering			
					E
					d
E	E E	G	H	68	
N	0	P	0		
S 72 DE EC	a	b	C	73	
EDURE 75	76 ATTENDING	NPI	a	JAL	
	LAST		FIRS"	г.	
EDURE DATE	77 OPERATING	NPI	a	JAL	
	LAST		FIRS	г.	
	78 OTHER	NPI	QL	JAL	
	LAST		FIRS"	г	
	79 OTHER	NPI	QL	JAL	
	LAST		FIRS		
Vational Uniform	THE CERTIFICATIO	NS ON THE REVERS	E APPLY TO THIS BI	LL AND ARE MADE A PART HEP	REOF.



Special Instructions for the On-body Injector (OBI) for Neulasta®

A healthcare provider must fill the on-body injector (OBI) with Neulasta® using the co-packaged prefilled syringe and then apply the OBI to the patient's skin (abdomen or back of arm). The back of the arm may only be used if there is a caregiver available to monitor the status of the OBI. Approximately 27 hours after the OBI is applied to the patient's skin, Neulasta[®] will be delivered over approximately 45 minutes. A healthcare provider may initiate administration with the OBI on the same day as the administration of cytotoxic chemotherapy, as long as the OBI delivers Neulasta® no less than 24 hours after the administration of cytotoxic chemotherapy.

The prefilled syringe co-packaged in the Neulasta® Onpro® kit contains additional solution to compensate for liquid loss during delivery through the OBI. If this syringe is used for manual subcutaneous injection, the patient will receive an overdose. If the prefilled syringe for manual use is used with the OBI, the patient may receive less than the recommended dose.

Do not use the OBI to deliver any other drug product except the Neulasta® prefilled syringe co-packaged with the OBI Use of the OBI has not been studied in pediatric patients.

The OBI should be applied to intact, non-irritated skin on the arm or abdomen.

A missed dose could occur due to an OBI failure or leakage. Instruct patients using the OBI to notify their healthcare professional immediately in order to determine the need for a replacement dose of pegfilgrastim if they suspect that the device may not have performed as intended. If the patient misses a dose, a new dose should be administered by single prefilled syringe for manual use as soon as possible after detection.

Review the Patient Information and Patient Instructions for Use with the patient and provide the instructions to the patient. Refer to the Healthcare Provider Instructions for Use for the OBI for full administration information.

For any OBI problems, call Amgen at 1-800-772-6436 or 1-844-MYNEULASTA (1-844-696-3852).

Indication and Important Safety Information for Neulasta[®] (pegfilgrastim) and NEUPOGEN[®] (filgrastim)

Indication

Neulasta® and NEUPOGEN® are indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. Neulasta[®] is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.

Important Safety Information

Contraindication

• Neulasta[®] or NEUPOGEN[®] are contraindicated in patients with a history of serious allergic reactions to human granulocyte colonystimulating factors (G-CSFs), such as pegfilgrastim or filgrastim

Splenic Rupture

- Splenic rupture, including fatal cases, can occur following the administration of Neulasta® and NEUPOGEN®
- Evaluate for an enlarged or ruptured spleen in patients who report left upper abdominal or shoulder pain

Acute Respiratory Distress Syndrome (ARDS)

- ARDS has occurred in patients receiving Neulasta®and NEUPOGEN®
- Evaluate patients who develop a fever and lung infiltrates or respiratory distress after receiving Neulasta® or NEUPOGEN®
- Discontinue Neulasta® or NEUPOGEN® in patients with ARDS

Serious Allergic Reactions

- Serious allergic reactions, including anaphylaxis can occur in patients receiving Neulasta® and NEUPOGEN®
- Provide symptomatic treatment for allergic reactions
- Majority of events occurred upon initial exposure and can recur within days after discontinuation of initial anti-allergic treatment

 Permanently discontinue Neulasta[®] or NEUPOGEN[®] in patients with serious allergic reactions

Allergies to Acrylics

- On-body Injector for Neulasta[®] uses acrylic adhesives
- Patients who are allergic to acrylic adhesives may have a significant reaction

Use in Patients with Sickle Cell Disorders

• In patients with sickle cell trait or disease, sickle cell crisis, in some cases fatal, can occur in patients receiving Neulasta® and NEUPOGEN[®]. Discontinue if sickle cell crisis occurs.

Glomerulonephritis

- Has occurred in patients receiving NEUPOGEN® and Neulasta®
- Diagnoses based on azotemia, hematuria, proteinuria, and renal biopsy
- Generally, events resolved after dose reduction or discontinuation of NEUPOGEN[®] and Neulasta[®]
- If suspected, evaluate for cause and if cause is likely, consider dose-reduction or interruption of Neulasta® or NEUPOGEN®

Capillary Leak Syndrome (CLS)

- CLS has been reported after G-CSF administration, including NEUPOGEN[®] and Neulasta[®]
- Characterized by hypotension, hypoalbuminemia, edema, and hemoconcentration
- Episodes vary in frequency, severity, and may be life-threatening if treatment is delayed
- Patients with symptoms should be closely monitored and receive standard symptomatic treatment, which may include intensive care

Thrombocytopenia

- Thrombocytopenia has been reported in patients who received NEUPOGEN[®] and pegfilgrastim
- Monitor platelet counts

Leukocytosis

- White blood cell counts of \geq 100,000/mm³ have been observed in patients who received NEUPOGEN® and Neulasta®
- Monitor CBCs during Neulasta[®] therapy and at least twice weekly for **NEUPOGEN®**
- Adjust NEUPOGEN[®] dosing as clinically indicated to help mitigate risk of leukocytosis
- Dosages of NEUPOGEN® that increase the absolute neutrophil count (ANC) beyond 10,000/mm³ may not result in any additional clinical benefit
- Discontinuation of NEUPOGEN[®] therapy usually resulted in a 50% decrease in circulating neutrophils within 1 to 2 days, with a return to pretreatment levels in 1 to 7 days

Cutaneous Vasculitis

- Moderate or severe cases of cutaneous vasculitis have been reported in patients treated with NEUPOGEN®
- Most reports involved patients with severe chronic neutropenia on long-term NEUPOGEN[®] therapy
- Hold NEUPOGEN[®] therapy in patients with cutaneous vasculitis
- NEUPOGEN[®] dose may be reduced when the symptoms resolve and ANC has decreased

Potential Effect on Malignant Cells

- G-CSF receptor has been found on tumor cell lines
- The possibility that NEUPOGEN[®] or Neulasta[®] acts as a growth factor for any tumor type, including myeloid malignancies and myelodysplasia, cannot be excluded

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Patients with Severe Chronic Neutropenia

- Confirm the diagnosis of SCN before initiating NEUPOGEN[®] therapy
- MDS and AML have been reported to occur in the natural history of congenital neutropenia without cytokine therapy
- Cytogenetic abnormalities, transformation to MDS, and AML have also been observed in patients treated with NEUPOGEN[®] for SCN • Based on available data including a postmarketing surveillance study.
- the risk of developing MDS and AML appears to be confined to the subset of patients with congenital neutropenia.
- Abnormal cytogenetics and MDS have been associated with the eventual development of myeloid leukemia
- The effect of NEUPOGEN[®] on the development of abnormal cytogenetics and the effect of continued NEUPOGEN[®] administration in patients with abnormal cytogenetics or MDS are unknown. Monitor patients for signs and symptoms of MDS/AML in these settings.
- If a patient with SCN develops abnormal cytogenetics or myelodysplasia, the risks and benefits of continuing NEUPOGEN® should be carefully considered

Patients with Breast and Lung Cancer

 MDS and AML have been associated with the use of NEUPOGEN[®] and Neulasta[®] in conjunction with chemotherapy and/or radiotherapy in patients with breast and lung cancer. Monitor patients for signs and symptoms of MDS/AML in these settings.

Please see additional Important Safety Information on page 11.

Simultaneous Use with Chemotherapy and Radiation **Therapy Not Recommended**

- Safety and efficacy of NEUPOGEN[®] given simultaneously with cytotoxic chemotherapy and radiation have not been established
- Do not use NEUPOGEN[®] 24 hours before or after cytotoxic chemotherapy
- Avoid simultaneous use of NEUPOGEN[®] with chemotherapy and radiation Nuclear Imaging
- Increased hematopoietic activity of the bone marrow has been associated with transient positive bone-imaging changes have been seen in patients taking Neulasta® or NEUPOGEN®.
- Consider when interpreting bone-imaging results

Potential Device Failures

- Missed or partial doses have been reported in patients receiving pegfilgrastim via the on-body injector (OBI) due to the device not performing as intended
- In the event of a missed or partial dose, patients may be at increased risk of events such as neutropenia, febrile neutropenia and/or infection than if the dose had been correctly delivered
- Instruct patients to notify their healthcare professional immediately in order to determine the need for a replacement dose if they suspect that the device may not have performed as intended

Aortitis

- Aortitis has been reported in patients receiving Neulasta[®] and NEUPOGEN[®]. It may occur as early as the first week after start of therapy.
- Manifestations may include generalized signs and symptoms such as fever, abdominal pain, malaise, back pain, and increased inflammatory markers (e.g., c-reactive protein and white blood cell count).
- Consider aortitis in patients who develop these signs and symptoms without known etiology. Discontinue Neulasta® and NEUPOGEN® if aortitis is suspected.

Most common adverse reactions in patients taking **NEUPOGEN®**

• Anemia, constipation, diarrhea, oral pain, vomiting, asthenia, malaise, peripheral edema, decreased hemoglobin, decreased appetite, oropharyngeal pain, and alopecia

Most common adverse reactions in patients taking **Neulasta®**

- Bone pain Pain in extremity
- NEUPOGEN® is administered by subcutaneous injection, short intravenous infusion (15 to 30 minutes), or continuous intravenous infusion
- Prefilled Syringe: Injection: 300 mcg/0.5 mL in a single-dose prefilled syringe; Injection: 480 mcg/0.8 mL in a single-dose prefilled syringe Neulasta® is administered by subcutaneous injection.
- Injection: 6 mg/0.6 mL in a single-dose prefilled syringe for manual use only.
- Injection: 6 mg/0.6 mL in a single-dose prefilled syringe co-packaged with the on-body injector (OBI) for Neulasta® (Neulasta® Onpro® kit).

Please see accompanying full Prescribing Information for Neulasta® and NEUPOGEN®.







See How We Can Help Your Patients

Offering the tools, information, and support for Amgen products that make a difference for you and your patients



BENEFIT VERIFICATION

Submit, store, and retrieve benefit verifications for all your patients currently on an Amgen product



AMGEN REIMBURSEMENT SPECIALISTS

Connect with an Amgen Reimbursement Counselor, or schedule a visit with a Field Reimbursement Specialist



AMGEN NURSE NAVIGATORS*

A single point of contact for Amgen Assist 360[™] services, designed to help your patients find the resources⁺ that are most important to them

* Amgen Nurse Navigators are only available to patients that are prescribed certain products. Nurse Navigators are there to support, not replace, your treatment plan and do not provide medical advice or case management services. Patients should always consult their healthcare provider regarding medical decisions or treatment concerns.

[†] Resources include referrals to independent nonprofit patient assistance programs. Eligibility for resources provided by independent nonprofit patient assistance programs is based on the nonprofits' criteria. Amgen has no control over these programs and provides referrals as a courtesy only.

Call 1-888-4ASSIST (888-427-7478) Monday to Friday, 9:00 AM to 8:00 PM EST, or visit www.AmgenAssist360.com

References

1. Neulasta® (pegfilgrastim) prescribing information, Amgen. 2. Neulasta® (pegfilgrastim) Onpro® kit Healthcare Provider Instructions for Use, Amgen. 3. RED BOOK Online®. Neulasta® (pegfilgrastim) injection Onpro® kit. https://www.micromedexsolutions.com/micromedex2/librarian/CS/62DD04/ND_PR/evidencexpert/ND_P/evidencexpert/ DUPLICATIONSHIELDSYNC/03D81D/ND_PG/evidencexpert/ND_B/evidencexpert/ND_AppProduct/evidencexpert/ND_T/evidencexpert/PFActionId/redbook.ShowProductSearc h Results? Search Term = NEULASTA%200N PRO & search Type = red book Product Name & search Term Id = 44479 & search Content = REDBOOK & search Filter AD = filter AD Active & search Filter & search Filter AD Active & search Filter &terRepackager=filterExcludeRepackager&searchPattern=%5Eneulasta. Accessed September 23, 2021. 4. RED BOOK Online®. Neulasta® (pegfilgrastim) injection. https://www. micromedexsolutions.com/micromedex2/librarian/CS/F14A98/ND_PR/evidencexpert/ND_P/evidencexpert/DUPLICATIONSHIELDSYNC/63A00B/ND_PG/evidencexpert/ND_B/ evidencexpert/ND_AppProduct/evidencexpert/ND_T/evidencexpert/PFActionId/redbook.ShowProductSearchResults?SearchTerm=NEULASTA&searchType=redbookProduct Name&searchTermId=30621&searchContent=REDBOOK&searchFilterAD=filterADActive&searchFilterRepackager=filterExcludeRepackager&searchPattern=%5ENeulasta. Accessed September 23, 2021. 5. Centers for Medicare & Medicaid Services. Healthcare Common Procedure Coding System (HCPCS) Application Summaries and Coding Decisions. https:// www.cms.gov/files/document/2021-hcpcs-application-summary-bi-annual-1-2021-non-drug-and-non-biological-items-and-services.pdf. Accessed November 1, 2021. 6. American Medical Association. Current Procedural Terminology (CPT®) 2021 Professional Edition. American Medical Association. 2020. 7. Value Healthcare Services. Understanding Hospital Revenue Codes. http://valuehealthcareservices.com/education/understanding-hospital-revenue-codes/. Accessed September 12, 2021. 8. Centers for Medicare & Medicaid Services. Medicare Claims Processing Manual - Chapter 25. Completing and Processing the Form CMS-1450 Data Set. Rev 4194. https://www.cms.gov/Regulations-and-Guidance/ Guidance/Manuals/downloads/clm104c25.pdf. Accessed September 12, 2021. 9. Centers for Medicare & Medicaid Services. Medicare Claims Processing Manual - Chapter 17: Drugs and Biologicals. Rev 10329. http://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/downloads/clm104c17.pdf. Accessed September 12, 2021. 10. Centers for Medicare & Medicaid Services. Medicare Program JW Modifier. https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/Downloads/JW-Modifier-FAQs.pdf. Accessed October 6, 2021. 11. Centers for Medicare & Medicard Services. Medicare-FFS Program. https://www.cms.gov/medicare/medicare-fee-for-servicepayment/hospitaloutpatientpps/downloads/billing-340b-modifiers-under-hospital-opps.pdf. Accessed October 6, 2021. 12. NEUPOGEN® (filgrastim) prescribing information, Amaen.



Amgen One Amgen Center Drive Thousand Oaks, CA 91320-1799 www.amgen.com

© 2021 Amgen Inc. All rights reserved. USA-OCF-81826 10/21







HOSPITAL OUTPATIENT CODING AND BILLING INFORMATION SHEET FOR NEULASTA® ONPRO®, NEULASTA®, AND NEUPOGEN®

Contact Amgen Assist 360[™] for reimbursement and access resources at 1-888-4ASSIST or www.AmgenAssist360.com

Neulasta[®] (pegfilgrastim) is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.¹


Neulasta[®] is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.¹

Neulasta[®] Onpro[®] kit, which includes: the same Neulasta[®] as in the Prefilled Syringe with a different delivery option¹



- Must be prepared and applied by a healthcare provider on the same day as chemotherapy¹
- The prefilled syringe co-packaged in the Neulasta[®] Onpro[®] kit must only be used with the On-body Injector for Neulasta[®]
- Designed to deliver a full dose of Neulasta® approximately 27 hours after its activation¹
 - As per the label, a healthcare provider may initiate administration with the On-body Injector for Neulasta[®] (also referred to as the "On-body Injector") on the same day as the administration of cytotoxic chemotherapy, and the On-body Injector is designed to deliver pegfilgrastim approximately 27 hours after application¹

Apply today, deliver* Neulasta® tomorrow¹



* The On-body Injector for Neulasta® is designed to deliver Neulasta® approximately 27 hours after activation.

Important Safety Information

Contraindication

 Neulasta[®] or NEUPOGEN[®] are contraindicated in patients with a history of serious allergic reactions to human granulocyte colony-stimulating factors (G-CSFs), such as pegfilgrastim or filgrastim



Please see additional Important Safety Information on pages 10-11.

Neulasta[®] delivered via the On-body Injector vs Neulasta[®] delivered via the manual use Neulasta[®] Prefilled Syringe

SELECT ATTRIBUTES	SAME	DIFFERENT
Active Ingredient ¹	\checkmark	
Indication ¹	\checkmark	
Route of Administration ¹	\checkmark	
Deliverable Dose ¹	\checkmark	
WAC ^{3,4}	\checkmark	
J-code ^{5,} *	\checkmark	
How Delivered and CPT Code ^{1,6,*}		\checkmark
NDC Number ^{1,*}		\checkmark

* See next page for coding and billing information sheet for Neulasta[®]. NDC = National Drug Code; WAC = wholesale acquisition cost.

On-body Injector for Neulasta®

A missed dose could occur due to an On-body Injector for Neulasta[®] failure or leakage. If the patient misses a dose, a new dose should be administered by single prefilled syringe for manual use, as soon as possible after detection.

The On-body Injector is backed by 24/7 telephone support and a full return policy.

Call **1-844-MYNEULASTA** at any time for assistance or answers to product-related questions.

Important Safety Information

Splenic Rupture

- Splenic rupture, including fatal cases, can occur following the administration of Neulasta® and NEUPOGEN®
- Evaluate for an enlarged or ruptured spleen in patients who report left upper abdominal or shoulder pain

Please see additional Important Safety Information on pages 10-11.



Hospital Outpatient – Billing Information Sheet for the Neulasta® Onpro® kit

ltem	Revenue Code ^{7,8}	Coding Information (HCPCS ⁵ /CPT ⁶ /ICD-10-CM)	Notes
Neulasta® Onpro® kit	Medicare: 0636, drugs	J2506 , injection, pegfilgrastim, excludes biosimilar, 0.5 mg	Neulasta [®] is supplied as a 6 mg deliverable dose. ¹
	requiring detailed coding ⁹		Effective Jan 1, 2022, the HCPCS has changed from J2505 to J2506,
	Other Payers: 0250, general pharmacy;		injection, pegfilgrastim, excludes biosimilar, 0.5 mg.
	OR 0636, if required by a given payer ⁹		55513-0192-01 is the NDC number (in the 11-digit format) for Neulasta® Onpro® kit. ¹
			Healthcare providers should ensure Service Units (Box 46) are appropriately billed.
Administration of the On-body Injector	Appropriate revenue code for the cost center in which the service is performed	96377, application of on-body injector (includes cannula insertion) for timed subcutaneous injection	Healthcare providers can initiate administration with the On-body Injector on the same day as the administration of chemotherapy. ^{1,*}
			See payer guidelines for specific coding requirements.
Diagnosis/ Condition	N/A	Appropriate ICD-10-CM diagnosis code(s) for patient condition.	Allowable diagnosis codes may vary by payer.

*As long as Neulasta® is not delivered between 14 days before and 24 hours after administration of cytotoxic chemotherapy.

CPT = Current Procedural Terminology; HCPCS = Healthcare Common Procedure Coding System; ICD-10-CM = International Classification of Diseases, Tenth Revision, Clinical Modification.


The information provided in this Coding and Billing Information document is of a general nature and for informational purposes only and is not intended to be a comprehensive list nor instructive. Coding and coverage policies change periodically and often without warning. The responsibility to determine coverage and reimbursement parameters, and appropriate coding for a particular patient and/or procedure, is always the responsibility of the provider or physician. The information provided in this section should in no way be considered a guarantee of coverage or reimbursement for any product or service.

Contact Amgen Assist 360[™] for reimbursement and access resources at 1-888-4ASSIST or www.AmgenAssist360.com



The CMS 1450 for Hospital Outpatient – the Neulasta® Onpro® kit

Sample UB-04 (CMS 1450) Form – Hospital Outpatient Administration



This sample form is intended as a reference for coding and billing for product and associated services. It is not intended to be a directive, nor does the use of the recommended codes guarantee reimbursement. Physicians and staff may deem other codes or policies more appropriate. Providers should select the coding options that most accurately reflect their internal system guidelines, payer requirements, practice patterns, and the services rendered. Providers are responsible for ensuring the accuracy and validity of all billing and claims for appropriate reimbursement.



Hospital Outpatient – Billing Information Sheet for the Neulasta® Prefilled Syringe

			· · · · · · · · · · · · · · · · · · ·
Item	Revenue Code ^{7,8}	Coding Information (HCPCS ⁵ /CPT ⁶ /ICD-10-CM)	Notes
Neulasta [®] Prefilled Syringe	Medicare: 0636, drugs	J2506 , injection, pegfilgrastim, excludes biosimilar, 0.5 mg	Neulasta [®] is supplied as a 6 mg deliverable dose. ¹
for Manual Injection	requiring detailed coding ⁹		Effective Jan 1, 2022, the HCPCS has changed from J2505 to J2506, injection, pegfilgrastim, excludes biosimilar, 0.5 mg.
	Other Payers: 0250, general pharmacy; OR 0636, if required by a		55513-0190-01 is the NDC number (in the 11-digit format) for the Neulasta [®] prefilled syringe for manual injection. ¹
	given payer ⁹		Healthcare providers should ensure Service Units (Box 46) are appropriately billed.
Administration of Neulasta [®] Prefilled Syringe for Manual Injection	Appropriate revenue code for the cost center in which the service is performed	96372, therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular	
Diagnosis/ Condition	N/A	Appropriate ICD-10-CM diagnosis code(s) for patient condition.	Allowable diagnosis codes may vary by payer.

The information provided in this Coding and Billing Information document is of a general nature and for informational purposes only and is not intended to be a comprehensive list nor instructive. Coding and coverage policies change periodically and often without warning. The responsibility to determine coverage and reimbursement parameters, and appropriate coding for a particular patient and/or procedure, is always the responsibility of the provider or physician. The information provided in this section should in no way be considered a guarantee of coverage or reimbursement for any product or service.

Important Safety Information

Acute Respiratory Distress Syndrome (ARDS)

- ARDS has occurred in patients receiving Neulasta[®] and NEUPOGEN[®]
- Evaluate patients who develop a fever and lung infiltrates or respiratory distress after receiving Neulasta[®] or NEUPOGEN[®]
- Discontinue Neulasta® or NEUPOGEN® in patients with ARDS

Please see additional Important Safety Information on pages 10-11.

Contact Amgen Assist 360[™] for reimbursement and access resources at 1-888-4ASSIST or www.AmgenAssist360.com



The CMS 1450 for Hospital Outpatient – the Neulasta® Prefilled Syringe

Sample UB-04 (CMS 1450) Form – Hospital Outpatient Administration

ample	000	- (-																
	wn Ho				2	2						3a PAT CNTL						4 TYPE OF BI
	lain S											b. MED REC. #		6 5	TATEMENT COV	EBS PERIO	D 17	
Inyto	wn, A	nysta	te O	1010								5 FED.	TAX NO.	F	ROM	THROUG	н Н	
PATIENT NAM	ME	a Smi	th,	Jane			9 PAT	IENT ADDRES	s i	123	8 Main	Stre	eet,	Anytown	, Anys	tate	1234	45
							b							-	c d			е
BIRTHDATE	1	1 SEX 12	DATE	ADMISSION 13 HR 14 T	YPE 15 S	RC 16 D	HR 17 STA	AT 18	19 2	0 21	CONDITIO 22	N CODES	24 25	26 27	28 29 AC 28 STA	DT 30 FE		_
OCCUB	BENCE	32 000	UBBENCE	33	OCCUBBI	ENCE	SER	VICE DA	TE (E	OX 4	5)	SP/	SERVI		(BOX 46)		
OCCURF DDE	DATE	32 OCC CODE	URRENCE DATE	33 CODE	OCCURRI	DATE	Repo			ce. Fo			Report	units of ser	vice for N	eulasta	a®	_
								nple, the	date v					rdance with				
														service un			lasta®	ODES
							injec	tion was	admır	histere	d. 	(dose is	6 mg, per l	abel.			
										b								
										c								
REV. CD.	43 DESCRIPTIC	N					44 HCF	PCS / RATE / HIPI	PS CODE	u u	45 SERV. DAT	E 46	6 SERV. UNIT:	S 47 TOTAL	. CHARGES	48 NO	V-COVERED	CHARGES 4
636							J2	2506			MMDE	YY	12	2	XXXX	x		
510	Clir	nic					96	5372			MMDE	YY	1		XXXX	x		
								,										
				42) AN	D		PRC	DUCT	COD	(BO	X 44)			PROCEDL	JRE COD	E (BO	X 44)	
	CRIPTIC	ONS (B	OX 43	3)				duct (J-						Related a	dminist	ration	proc	edure
Prod								06, inject										
				le 0636,	drugs	5	excl	udes bio		, 0.5 r	ng.		_	procedure				
								t e: If app						therapeution (s				
				code 02							rted on a			subcutaneo				uy),
	rai phari en payei		r 0636	5, if requi	irea by	у		arate line	e with	J2506	5 and the						. circar	
	en payei						11.17	modifior										
Dele	اممامه				مىربار			modifier.										
		ministr		procec			Wh	en applic	able,		5 modifie icare	r						
Use n	nost app	ministr propriate		n procec nue code ces were			Wh sho	en applic uld be us	able, sed or	n Med								
Use n for co	nost app	ministr propriate er where		nue code ces were		E	Wh sho hos	en applic uld be us pital out	able, sed or patier	n Med It clain	icare	for						
Use n for co	most app ost cente	ministr propriate er where		nue code ces were			Who show hos cert (incl	en applic uld be us pital out ain sepa luding N	cable, sed or patier rately eulast	n Med It clain payab a®) ac	icare ns to bill ble drugs quired	for						
Use n for co	most app ost cente	ministr propriate er where		nue code ces were			Who show hos cert (incl	en applic uld be us pital out ain sepa	cable, sed or patier rately eulast	n Med It clain payab a®) ac	icare ns to bill ble drugs quired	for						
Use n for co	most app ost cente	ministr propriate er where		nue code ces were			Who show hos cert (incl	en applic uld be us pital out ain sepa luding N	cable, sed or patier rately eulast	n Med It clain payab a®) ac	icare ns to bill ble drugs quired	for						
Use n for co perfo	most app ost cente ormed (e	ministr propriate er where g, 0510	e rever e servio , clinic	nue code ces were			Who show hos cert (incl	en applic uld be us pital out ain sepa luding N bugh the	cable, sed or patier rately eulast 340B	n Med at clain payab a®) ac progr	icare ns to bill ble drugs quired	for						
Use n for co perfo	most app ost cente prmed (e PAGE _	ministr propriate er where	e rever e servio , clinic	nue code ces were	2		Who shou cert (incl thrc	en applic uld be us pital out ain sepa luding N	cable, sed or patier rately eulast 340B	n Med at clain payab a®) ac progr DATE	icare ns to bill ole drugs quired ram. ¹¹	for 7	TOTALS					
Use n for co perfo	most app ost cente prmed (e PAGE _	ministr propriate er where g, 0510	e rever e servio , clinic	nue code ces were	2	ALTH PLAN	Who shou cert (incl thrc	en applic uld be us pital out ain sepa luding N bugh the	able, sed or patier rately eulast 340B	n Med at clain payab a®) ac progr DATE	icare ns to bill ble drugs quired	for 7	_	MOUNT DUE	56 NPI			
Use n for co perfo	most app ost cente prmed (e PAGE _	ministr propriate er where g, 0510	e rever e servio , clinic	nue code ces were	2	ALTH PLAN	Who shou cert (incl thrc	en applic uld be us pital out ain sepa luding N bugh the	able, sed or patier rately eulast 340B	n Med at clain payab a®) ac progr DATE	icare ns to bill ole drugs quired ram. ¹¹	for 7	_		56 NPI 57 07HER			
Use n for co perfo	most app ost cente prmed (e PAGE _	ministr propriate er where g, 0510	e rever e servio , clinic	nue code ces were	2	ALTH PLAN	Who shou cert (incl thrc	en applic uld be us pital out ain sepa luding N bugh the	able, sed or patier rately eulast 340B	n Med at clain payab a®) ac progr DATE	icare ns to bill ole drugs quired ram. ¹¹	for 7	_		57			
Use n for cc perfo	nost app ost cente prmed (e PAGE_ we	ministr oropriate er where eg, 0510	e rever e servio , clinic	ue code ces were :).	2	ALTH PLAN	Who shou cert (incl thrc	en applic uld be us pital out ain sepa luding N bugh the	able, sed or patier rately eulast 340B	n Med at clain payab a®) ac progr DATE	icare ns to bill ole drugs quired ram. ¹¹	for 7	55 EST. A		57 OTHER PRV ID	NCE GROUI	P NO.	
Use n for cc perfo	nost app ost cente prmed (e PAGE _ we	ministr oropriate er where eg, 0510	e rever e servio , clinic	ue code ces were :).	2		Who shou cert (incl thrc	en applid uld be us pital out ain sepa luding N bugh the CREA	able, sed or patier rately eulast 340B	n Med at clain payab a®) ac progr DATE	icare ns to bill ole drugs quired ram. ¹¹	for 7 NTS	55 EST. A		57 OTHER PRV ID	NCE GROUI	P NO.	
Use n for cc perfo Payer NAM	Most app ost cente prmed (e PAGE_ ME ME SNOSIS r approp	originate oropriate er where og, 0510 01 01 5 CODE	e rever e servia , clinic		2		Who shou cert (incl thrc	en applid uld be us pital out ain sepa luding N bugh the CREA	able, sed or patier rately eulast 340B	n Med at clain payab a®) ac progr DATE	icare ns to bill ole drugs quired ram. ¹¹	for 7 NTS	55 EST. A		57 OTHER PRV ID	NCE GROUI	P NO.	
Use n for cc perfo PAYER NAME NSUREDS. DIAC Enter diagn	Most app ost cente prmed (e PAGE_ ME NAME GNOSIS r approp nosis coc	orpriate er where eg, 0510 0/ 5 CODE rriate ICI de(s) cor	s (BC D-10-C resport		2		Who shoc cert (incl thrc	en applid uld be us pital out ain sepa luding N bugh the CREA	rable, rable, sed or patier rately eulast 3408	Med t clain payab a®) ac progr	icare ns to bill ole drugs quired ram. ¹¹	for 7 NTS	55 EST. A	MOUNT DUE	57 OTHER PRV ID 62 INSURA	NCE GROUI	P NO.	
Use n for co perfo	Most app ost cente prmed (e PAGE_ ME SNAME GNOSIS r approp nosis coo atient's d	originalistr propriate er where og, 0510 originalist originalist originalist originalist originalist	s (BC S (BC D-10-C resport Allow	vue code ces were c). 	2		Who shoc cert (incl thrc	en applid uld be us pital out ain sepa luding N bugh the CREA	rable, rable, sed or patier rately eulast 3408	Med t clain payab a®) ac progr	icare ns to bill ole drugs quired ram. ¹¹	for 7 NTS	55 EST. A		57 OTHER PRV ID 62 INSURA	NCE GROUI	P NO.	
Use n for co perfo	Most app ost cente prmed (e PAGE_ ME SNAME GNOSIS r approp nosis coo atient's d	originalistr propriate er where og, 0510 originalist originalist originalist originalist originalist	s (BC S (BC D-10-C resport Allow		2		Who shoc cert (incl thrc	en applid uld be us pital out ain sepa luding N bugh the CREA	rable, rable, sed or patier rately eulast 3408	Med t clain payab a®) ac progr	icare ns to bill ole drugs quired ram. ¹¹	for 7 NTS	55 EST. A	MOUNT DUE	57 OTHER PRV ID 62 INSURA	NCE GROUI	P NO.	
Use n for co perfo	Most app ost cente prmed (e PAGE_ ME SNAME GNOSIS r approp nosis coo atient's d	originalistr propriate er where og, 0510 originalist originalist originalist originalist originalist	s (BC S (BC D-10-C resport Allow	vue code ces were c). 	2		Who shoc cert (incl thrc	en applid uld be us pital out ain sepa luding N bugh the CREA	rable, rable, sed or patier rately eulast 3408	Med t clain payab a®) ac progr	icare ns to bill ole drugs quired ram. ¹¹	for 7 NTS	55 EST. A	MOUNT DUE	57 OTHER PRV ID 62 INSURA	NCE GROUI		
INSUBEDS. DIAC Enter diagn to pai	Most app ost cente prmed (e PAGE _ Me Me GNOSIS r approp nosis coo itient's d nosis coo	originalistr propriate er where og, 0510 originalist originalist originalist originalist originalist	s (BC S (BC D-10-C resport Allow	vue code ces were c). 	2		Who shoc cert (incl thrc	en applid uld be us pital out ain sepa luding N bugh the CREA	rable, rable, sed or patier rately eulast 3408	Med t clain payab a®) ac progr	icare ns to bill ole drugs quired ram. ¹¹	for 7 NTS	55 EST. A	MOUNT DUE	57 OTHER PRV ID 62 INSURA	NCE GROUI	68	
PAYER NAM	Most app ost cente prmed (e PAGE _ Me Me GNOSIS r approp nosis coo itient's d nosis coo	originalistic propriate er where g, 0510 originalistic state ICI de(s) cor liagnosis des may data des may	e rever e servia , clinic 5 (BC D-10-C respor . Allov vary b	vue code ces were c). 	2		Who shoc cert (incl thrc	en applid uld be us pital out ain sepa luding N bugh the CREA	able, sed or patier rately eulast 340B	Med t clain payab a®) ac progr	icare ns to bill le drugs quired ram. ¹¹	for 7 NTS	55 EST. A	MOUNT DUE	57 OTHER PRV ID 62 INSURA	NCE GROUI	68	
NSUBED'S PAYER NAM	Most app ost cente prmed (e PAGE_ Me GNOSIS r approp nosis coo atient's d nosis coo	originality oropriate er where og, 0510 or or or or or or or or or or or or or	e rever e servia , clinic 5 (BC D-10-C respor . Allov vary b			59 P. REL	<pre>Whiteshowshowshowshowshowshowshowshowshowshow</pre>	en applid uld be us pital out ain sepa luding N bugh the CREA	TION TION TION TION TION TION TION TION TION TION TION TION TION TION TION TION	Meddut clain payab a®) acc progr DATE SX400 SX400 SX400 SX400 SX400 SX400 SX400 SX400 SX400 SX400 SX400 SX400 SX400 SX400 SX400 SX400 SX40 SX4	icare ns to bill ole drugs quired ram. ¹¹	for 77	JP NAME	65 EMPLOYER F	57 OTHER PRV ID 62 INSURA	H		
PAYER NAM	Most app ost cente prmed (e PAGE _ Me Me GNOSIS r approp nosis coo itient's d nosis coo	originality oropriate er where og, 0510 or or or or or or or or or or or or or	e rever e servia , clinic 5 (BC D-10-C respor . Allov vary b	vue code ces were c). 		59 P. REL	Who shoc cert (incl thrc	en applid uld be us pital out ain sepa luding N bugh the CREA	TION TION TION TION TION TION TION TION TION TION TION TION TION TION TION TION	Meddut clain payab a®) acc progr DATE SX400 SX400 SX400 SX400 SX400 SX400 SX400 SX400 SX400 SX400 SX400 SX400 SX400 SX400 SX400 SX400 SX40 SX4	icare ns to bill le drugs quired ram. ¹¹	for 7 81 GROU	55 EST. A	MOUNT DUE	57 OTHER PRV ID 62 INSURA	QUAL	68	
PAYER NAM	NAME PAGE_ ME NAME GNOSIS r approp nosis coo tient's d nosis coo tient's d nosis coo	Comprise or opriate or opria	e rever e servia , clinic 5 (BC D-10-C respor . Allov vary b	A coperation of the second sec	2 51 HEA 	59 P. REL	<pre>Whiteshowshowshowshowshowshowshowshowshowshow</pre>	en applid uld be us pital out ain sepa luding N bugh the CREA	TION STEL	Meddit clain payab action of the second sec	icare ns to bill le drugs quired ram. ¹¹	for 7 7 61 GROU	55 EST, A	65 EMPLOYER F	57 OTHER PRV ID 62 INSURA	H	68	
PAYER NAM	Most app ost cente prmed (e PAGE_ Me GNOSIS r approp nosis coo atient's d nosis coo	Comprise or opriate or opria	e rever e servia , clinic 5 (BC D-10-C respor . Allov vary b		2 51 HEA 	59 P. REL	White show the second s	en applid uld be us pital out ain sepa luding N bugh the CREA	TION STEL	Meddit clain payab action of the second sec	icare ns to bill le drugs quired ram. ¹¹	for 7 7 61 GROU	55 EST, A	65 EMPLOYER 1	57 OTHER PRV ID 62 INSURA	QUAL	68	
NSURED'S PAYER NAM	NAME PAGE_ ME NAME GNOSIS r approp nosis coo tient's d nosis coo tient's d nosis coo	Comprise or opriate or opria	e rever e servia , clinic 5 (BC D-10-C respor . Allov vary b	A coperation of the second sec	2 51 HEA 	S9 P. REL	White show the second s	en applid uld be us pital out ain sepa luding N bugh the CREA	TION STEL	Meddit clain payab action of the second sec	icare ns to bill le drugs quired ram. ¹¹	for 7 7 81 GROU 81 GROU 81 GROU 81 GROU 81 GROU 81 GROU	55 EST, A	65 EMPLOYER 1	57 OTHER PRV ID 62 INSURA	QUAL FIRST QUAL	68	
NSURED'S PAYER NAM PAYER NAM NSURED'S DIAC Enter diagn to pa diagn XXX	NAME PAGE_ ME NAME GNOSIS r approp nosis coo tient's d nosis coo tient's d nosis coo	Comprise or opriate or opria	e rever e servia , clinic 5 (BC D-10-C respor . Allov vary b	A coperation of the second sec		59 P. REL	White show the second s	en applid uld be us pital out ain sepa luding N bugh the CREA	TION STEL	Meddit clain payab action of the second sec	icare ns to bill le drugs quired ram. ¹¹	for 7 7 81 авои 61 авои 26 ат 1 авт 1 аве	55 EST, A	65 EMPLOYER I 65 International Control of Co	57 OTHER PRV ID 62 INSURA	QUAL FIRST QUAL FIRST	68	
PAYER NAM	NAME PAGE_ ME NAME GNOSIS r approp nosis coo tient's d nosis coo tient's d nosis coo	Comprise or opriate or opria	e rever e servia , clinic 5 (BC D-10-C respor . Allov vary b	A coperation of the second sec	S 1 HEA	E DATE	White show the second s	en applid uld be us pital out ain sepa luding N bugh the CREA	TION STEL	Meddit clain payab action of the second sec	icare ns to bill le drugs quired ram. ¹¹	61 GROU 7 AT 1 CAST 7 OP LAST 7 OP	55 EST, A	65 EMPLOYER I 65 International Control of Co	57 OTHER PRV ID 62 INSURA	QUAL FIRST QUAL FIRST QUAL	68	
D PAYER NAM	NAME PAGE NAME RONOSIS PAGE PAGE NAME NAME NAME NAME NAME NAME NAME NAM	CODE	s rever servid , clinic s s (BC D-10-C respor . Allov vary b s a a d d	A coperation of the second sec		RE DATE	White show the second s	en applid uld be us pital out ain sepa luding N bugh the CREA	TION STEL	I Med I Clain payab a®) ac progr	icare ns to bill le drugs quired ram. ¹¹	61 GROU 61	55 EST, A	65 EMPLOYER I	57 OTHER PRV ID 62 INSURA WAME	QUAL OUAL FIRST OUAL FIRST OUAL FIRST	68 73	

This sample form is intended as a reference for coding and billing for product and associated services. It is not intended to be a directive, nor does the use of the recommended codes guarantee reimbursement. Physicians and staff may deem other codes or policies more appropriate. Providers should select the coding options that most accurately reflect their internal system guidelines, payer requirements, practice patterns, and the services rendered. Providers are responsible for ensuring the accuracy and validity of all billing and claims for appropriate reimbursement.





Hospital Outpatient – Billing Information Sheet for NEUPOGEN®

NEUPOGEN® (filgrastim) is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever.¹²

Item	Revenue Code ^{7,8}	Coding Information (HCPCS ⁵ /CPT ⁶ /ICD-10-CM)	Notes
NEUPOGEN®	Medicare: 0636, drugs requiring detailed coding ⁹	J1442, injection, filgrastim (G-CSF), 1 mcg	The NDC numbers for NEUPOGEN [®] , in the 11-digit format, are as follows: ¹² - 300-mcg vial: 55513-0530-10 - 300-mcg prefilled syringe: 55513-0924-10 - 480-mcg vial: 55513-0546-10
	Other Payers: 0250, general pharmacy; OR 0636, if required by a given payer ⁹		- 480-mcg prefilled syringe: 55513-0209-10
Administration	Appropriate revenue code for the cost center in which the service is performed	96372, therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular	
Diagnosis/ Condition	N/A	Appropriate ICD-10-CM diagnosis code(s) for patient condition.	Allowable diagnosis codes may vary by payer.

Important Safety Information

Serious Allergic Reactions

- Serious allergic reactions, including anaphylaxis can occur in patients receiving Neulasta® and NEUPOGEN®
- Provide symptomatic treatment for allergic reactions
- Majority of events occurred upon initial exposure and can recur within days after discontinuation of initial anti-allergic treatment
- Permanently discontinue Neulasta® or NEUPOGEN® in patients with serious allergic reactions

Please see additional Important Safety Information on pages 10-11.

Contact Amgen Assist 360[™] for reimbursement and access resources at 1-888-4ASSIST or www.AmgenAssist360.com



The CMS 1450 for Hospital Outpatient – NEUPOGEN®

Sample UB-04 (CMS 1450) Form – Hospital Outpatient Administration

Anytown Hospital 100 Main Street	2		3a CN b.M	MED. C. #				4 TYPE OF BILL	
Anytown, Anystate 01010				ED. TAX NO.	6 STATE FRO	EMENT COVERS	PERIOD 7 ROUGH		
• · •									
ATIENT NAME a Smith, Jane	9 PATIENT AD	DDRESS a 1	23 Main Str	ceet, An	lytown, i	Anystat	e 1234	5	
BIRTHDATE 11 SEX 12 DATE ADMISSION 13 HR 14 TYPE 1	15 SRC 16 DHR 17 STAT 18	8 19 20	CONDITION CODE 21 22 23	S		29 ACDT 3	0	e	
				SERVICE	UNITS (B	OX 46)			
OCCURRENCE 32 OCCURRENCE 33 OCCU DDE DATE CODE DATE CODE	URRENCE 34 OCCUP DATE CODE	DATE 35	OCCURRENCE SP4	Report un	nits of servic	e.	37		
					J1442 corr				а
			39 VALUE CODE CODE AMOUNT	1 mcg of	NEUPOGEN for the 300			CODES	b
			a AMOUNT		for the 480			OUNT	
			b						
			c						
			d la annu a una				TOTAL	CUADO	- C (D O
REV. CD. 43 DESCRIPTION 636	J144	TE / HIPPS CODE	45 SERV. DATE	46 SERV. UNITS	47 TOTAL CHA	XXXXXX		CHARGE	
510 Clinic	9637		MMDDYY			XXXXXX		appropria [.] luct used	
	5037	-	1410011			nnn nn	procedu		anu re
ΤΙΤ							procedu	ires.	
REVENUE CODES (BOX 42) AND	PRO	DUCT AND	PROCEDURE	CODE (BC)X 44)				8
DESCRIPTIONS (BOX 42) AND		duct (J-Code							
Product			-) ilgrastim (G-CSF	.), 1 mca					
Medicare: Use revenue code 0636, dru			e, discarded pro		ld he renor	rtod			4
requiring detailed coding.			with J1442 and			ieu			1
									1
Other payers: Use revenue code 0250,		annlicable	the I(1 modute						
general pharmacy (or 0636, if required	VVIIC		the JG modifie l outpatient clai						1
general pharmacy (or 0636, if required a given payer).	l by Med sepa	licare hospita arately payabl	l outpatient clai e drugs (includii	ms to bill f	or certain	ired			1
general pharmacy (or 0636, if required a given payer). Related administration procedure	l by Med sepa	licare hospita	l outpatient clai e drugs (includii	ms to bill f	or certain	uired			1
general pharmacy (or 0636, if required a given payer). Related administration procedure Use most appropriate revenue code	re Rela	licare hospita arately payabl ugh the 340E ated admini	l outpatient clai e drugs (includii 3 program. ¹¹ stration proce	ms to bill fo ng NEUPOO edure	or certain GEN®) acqu				1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
general pharmacy (or 0636, if required a given payer). Related administration procedure Use most appropriate revenue code for cost center where services were	I by Med sepa re throu Rela	licare hospita arately payabl ugh the 340E ated admini CPT [®] code rep	l outpatient clai e drugs (includii 3 program. ¹¹ stration proce presenting proce	ms to bill fong NEUPOO e dure edure perfo	or certain GEN®) acqu irmed, such	as			1 1 1 1 1
general pharmacy (or 0636, if required a given payer). Related administration procedure Use most appropriate revenue code	I by Med sepa re throu Rela Use 0 9637	dicare hospita arately payabl ugh the 340E ated admini CPT [®] code rep 72, therapeut	l outpatient clai e drugs (includii b program. ¹¹ stration proce presenting proce c, prophylactic,	ms to bill fo ng NEUPOO edure edure perfo or diagnost	or certain GEN®) acqu rmed, such tic injection	as			1 1 1 1 1 1
general pharmacy (or 0636, if required a given payer). Related administration procedure Use most appropriate revenue code for cost center where services were	I by Med sepa re throu Rela Use 0 9637	dicare hospita arately payabl ugh the 340E ated admini CPT [®] code rep 72, therapeut	l outpatient clai e drugs (includii 3 program. ¹¹ stration proce presenting proce	ms to bill fo ng NEUPOO edure edure perfo or diagnost	or certain GEN®) acqu rmed, such tic injection	as			
general pharmacy (or 0636, if required a given payer). Related administration procedure Use most appropriate revenue code for cost center where services were	I by Med sepa re throu Rela Use 0 9637	dicare hospita arately payabl ugh the 340E ated admini CPT [®] code rep 72, therapeut	l outpatient clai e drugs (includii b program. ¹¹ stration proce presenting proce c, prophylactic,	ms to bill fo ng NEUPOO edure edure perfo or diagnost	or certain GEN®) acqu rmed, such tic injection	as			1 1 1 1 1 1 1 1 1 2 2
general pharmacy (or 0636, if required a given payer). Related administration procedure Use most appropriate revenue code for cost center where services were	I by Med sepa re throu Rela Use 0 9637	dicare hospita arately payabl ugh the 340E ated admini CPT [®] code rep 72, therapeut	l outpatient clai e drugs (includii b program. ¹¹ stration proce presenting proce c, prophylactic,	ms to bill fo ng NEUPOO edure edure perfo or diagnost	or certain GEN®) acqu rmed, such tic injection	as			1 1 1 1 1 1 1 1 1 2 2 2 2
general pharmacy (or 0636, if required a given payer). Related administration procedure Use most appropriate revenue code for cost center where services were performed (eg, 0510, clinic).	i by Med sepa re throu Rela Use (9637 (spec	dicare hospita arately payabl ugh the 340E ated admini CPT® code rep 72, therapeut cify substance	l outpatient clai e drugs (includii program. ¹¹ stration proce presenting proce c, prophylactic, or drug); subcu	ms to bill fung NEUPOO edure edure perfo or diagnost taneous or TOTALS	or certain GEN®) acqu rmed, such tic injection intramuscu	as			1 1 1 1 1 1 1 1 2 2 2 2
general pharmacy (or 0636, if required a given payer). Related administration procedure Use most appropriate revenue code for cost center where services were performed (eg, 0510, clinic).	i by Med sepa re throu Rela Use (9637 (spec	dicare hospita arately payabl ugh the 340E ated admini CPT® code rep 72, therapeut cify substance	l outpatient clai e drugs (includin program. ¹¹ stration proce presenting proce c, prophylactic, or drug); subcu	ms to bill fung NEUPOC edure edure perfo or diagnost taneous or	or certain GEN®) acqu rmed, such tic injection intramuscu	as ular 56 NPI			1 1 1 1 1 1 1 1 1 2 2 2 2 2 2 2 2
general pharmacy (or 0636, if required a given payer). Related administration procedure Use most appropriate revenue code for cost center where services were performed (eg, 0510, clinic). PAGE OF	i by Med sepa re throu Rela Use (9637 (spec	dicare hospita arately payabl ugh the 340E ated admini CPT® code rep 72, therapeut cify substance	l outpatient clai e drugs (includii program. ¹¹ stration proce presenting proce c, prophylactic, or drug); subcu	ms to bill fung NEUPOO edure edure perfo or diagnost taneous or TOTALS	or certain GEN®) acqu rmed, such tic injection intramuscu	as Jular 56 NPI 57			
general pharmacy (or 0636, if required a given payer). Related administration procedure Use most appropriate revenue code for cost center where services were performed (eg, 0510, clinic).	i by Med sepa re throu Rela Use (9637 (spec	dicare hospita arately payabl ugh the 340E ated admini CPT® code rep 72, therapeut cify substance	l outpatient clai e drugs (includii program. ¹¹ stration proce presenting proce c, prophylactic, or drug); subcu	ms to bill fung NEUPOO edure edure perfo or diagnost taneous or TOTALS	or certain GEN®) acqu rmed, such tic injection intramuscu	aS Jlar 56 NPI 57 0THER			
general pharmacy (or 0636, if required a given payer). Related administration procedure Use most appropriate revenue code for cost center where services were performed (eg, 0510, clinic). PAGE OF XYER NAME 511	i by Med sepa re throu Rela Use (9637 (spec	dicare hospita arately payabl ugh the 340E ated admini CPT® code rep 72, therapeut cify substance	l outpatient clai e drugs (includii 8 program. ¹¹ stration proce c, prophylactic, or drug); subcu	ms to bill fung NEUPOO edure edure perfo or diagnost taneous or TOTALS	or certain GEN®) acqu rmed, such tic injection intramuscu	as Jular 56 NPI 57	SROUP NO.		
general pharmacy (or 0636, if required a given payer). Related administration procedure Use most appropriate revenue code for cost center where services were performed (eg, 0510, clinic). PAGE OF XYER NAME 511	i by Med sepa re throu Rela Use (9637 (spec	dicare hospita arately payabl ugh the 340E ated admini CPT® code rep 72, therapeut cify substance	l outpatient clai e drugs (includii 8 program. ¹¹ stration proce c, prophylactic, or drug); subcu	ms to bill fung NEUPOO edure perfo or diagnosi taneous or TOTALS	or certain GEN®) acqu rmed, such tic injection intramuscu	aS Jlar 56 NPI 57 0THER PRV ID	SROUP NO.		
general pharmacy (or 0636, if required a given payer). Related administration procedure Use most appropriate revenue code for cost center where services were performed (eg, 0510, clinic). PAGEOF WYER NAME 511 NSUBEDIS NAME	i by Med sepa re throu Rela Use (9637 (spec	dicare hospita arately payabl ugh the 340E ated admini CPT® code rep 72, therapeut cify substance	l outpatient clai e drugs (includii 8 program. ¹¹ stration proce c, prophylactic, or drug); subcu	ms to bill fung NEUPOO edure perfo or diagnosi taneous or TOTALS	or certain GEN®) acqu rmed, such tic injection intramuscu	aS Jlar 56 NPI 57 0THER PRV ID	SROUP NO.		
general pharmacy (or 0636, if required a given payer). Related administration procedure Use most appropriate revenue code for cost center where services were performed (eg, 0510, clinic). PAGEOF AVER NAMESI = NELURED'S NAME DIAGNOSIS CODES (BOX 67) Enter appropriate ICD-10-CM diagnosis code(s) corresponding	i by Med sepa re Rela Use 0 9637 (spec HEALTH PLAN ID	dicare hospita arately payabl ugh the 340E ated admini CPT® code rep 72, therapeut cify substance <u>CREATION DA</u>	I outpatient clai e drugs (includie program. ¹¹ stration proce c, prophylactic, or drug); subcu	ms to bill fund ng NEUPOO edure perfo or diagnost taneous or TOTALS 55 EST. AMOU	or certain GEN®) acqu rmed, such tic injection intramuscu unr DUE	as Jlar 56 NPI 57 0THER PRV ID 62 INSURANCE O	SROUP NO,		
general pharmacy (or 0636, if required a given payer). Related administration procedure Use most appropriate revenue code for cost center where services were performed (eg, 0510, clinic). PAGE	i by Med sepa re Rela Use 0 9637 (spec HEALTH PLAN ID	dicare hospita arately payabl ugh the 340E ated admini CPT® code rep 72, therapeut cify substance	I outpatient clai e drugs (includie program. ¹¹ stration proce c, prophylactic, or drug); subcu	ms to bill fund ng NEUPOO edure perfo or diagnost taneous or TOTALS 55 EST. AMOU	or certain GEN®) acqu rmed, such tic injection intramuscu	as Jlar 56 NPI 57 0THER PRV ID 62 INSURANCE O	SROUP NO,		
general pharmacy (or 0636, if required a given payer). Related administration procedure Use most appropriate revenue code for cost center where services were performed (eg, 0510, clinic). PAGEOF AVER NAMESI = NELURED'S NAME DIAGNOSIS CODES (BOX 67) Enter appropriate ICD-10-CM diagnosis code(s) corresponding	i by Med sepa re Rela Use 0 9637 (spec HEALTH PLAN ID	dicare hospita arately payabl ugh the 340E ated admini CPT® code rep 72, therapeut cify substance <u>CREATION DA</u>	I outpatient clai e drugs (includie program. ¹¹ stration proce c, prophylactic, or drug); subcu	ms to bill fund ng NEUPOO edure perfo or diagnost taneous or TOTALS 55 EST. AMOU	or certain GEN®) acqu rmed, such tic injection intramuscu unr DUE	as Jlar 56 NPI 57 0THER PRV ID 62 INSURANCE O	SROUP NO,		
general pharmacy (or 0636, if required a given payer). Related administration procedure Use most appropriate revenue code for cost center where services were performed (eg, 0510, clinic). PAGEOF VER NAMESI DIAGNOSIS CODES (BOX 67) Enter appropriate ICD-10-CM diagnosis code(s) corresponding to patient's diagnosis. Allowable	i by Med sepa re Rela Use 0 9637 (spec HEALTH PLAN ID	dicare hospita arately payabl ugh the 340E ated admini CPT® code rep 72, therapeut cify substance <u>CREATION DA</u>	I outpatient clai e drugs (includie program. ¹¹ stration proce c, prophylactic, or drug); subcu	ms to bill fund ng NEUPOO edure perfo or diagnost taneous or TOTALS 55 EST. AMOU	or certain GEN®) acqu rmed, such tic injection intramuscu unr DUE	as Jlar 56 NPI 57 0THER PRV ID 62 INSURANCE O	BROUP NO,		
general pharmacy (or 0636, if required a given payer). Related administration procedure Use most appropriate revenue code for cost center where services were performed (eg, 0510, clinic). PAGEOF PAGEOF VELIGEDES NAME DIAGNOSIS CODES (BOX 67) Enter appropriate ICD-10-CM diagnosis code(s) corresponding to patient's diagnosis. Allowable diagnosis codes may vary by payer.	i by Med sepa re Rela Use 0 9637 (spec HEALTH PLAN ID	dicare hospita arately payabl ugh the 340E ated admini CPT® code rep 72, therapeut cify substance <u>CREATION DA</u>	I outpatient clai e drugs (includie program. ¹¹ stration proce c, prophylactic, or drug); subcu	ms to bill fund ng NEUPOO edure perfo or diagnost taneous or TOTALS 55 EST. AMOU	or certain GEN®) acqu rmed, such tic injection intramuscu unr DUE	as Jlar 56 NPI 57 0THER PRV ID 62 INSURANCE O	BROUP NO,		
general pharmacy (or 0636, if required a given payer). Related administration procedure Use most appropriate revenue code for cost center where services were performed (eg, 0510, clinic). PAGE OF VER NAME DIAGNOSIS CODES (BOX 67) Enter appropriate ICD-10-CM diagnosis code(s) corresponding to patient's diagnosis. Allowable diagnosis codes may vary by payer. XXX.X A B	i by Med sepa re Rela Use 0 9637 (spec HEALTH PLAN ID	dicare hospita arately payabl ugh the 340E ated admini CPT® code reg 72, therapeut cify substance REATION DA BREEL BAR INFO BREEL INFO BREEL INFO BREEL INFO BREEL INFO BREEL INFO BREEL	I outpatient clai e drugs (includie program. ¹¹ stration proce c, prophylactic, or drug); subcu	ms to bill fund ng NEUPOO edure perfo or diagnost taneous or TOTALS 55 EST. AMOU	or certain GEN®) acqu rmed, such tic injection intramuscu unr DUE	as Jlar 56 NPI 57 0THER PRV ID 62 INSURANCE O	68		
general pharmacy (or 0636, if required a given payer). Related administration procedure Use most appropriate revenue code for cost center where services were performed (eg, 0510, clinic). PAGE OF VER NAME DIAGNOSIS CODES (BOX 67) Enter appropriate ICD-10-CM diagnosis code(s) corresponding to patient's diagnosis. Allowable diagnosis codes may vary by payer. XXX.X A MIT	t by Med sepa re Rela Use 0 9637 (spec HEALTH PLAN ID 59 R.REL 60 INSURED'S U 64 DOCUM	dicare hospita arately payabl ugh the 340E ated admini CPT® code rep 72, therapeuti cify substance CREATION DA BER BER BER BER BER BER BER BER BER BE	I outpatient clai e drugs (includie program. ¹¹ stration proce presenting proce c, prophylactic, or drug); subcu	ms to bill fund NEUPOO	or certain GEN®) acqu rmed, such tic injection intramuscu intramuscu intramuscu ses employer NAM	as ,lar 56 NPI 57 07HER PRV ID 62 INSURANCE O 62 INSURANCE O 62 INSURANCE O	68 73		
general pharmacy (or 0636, if required a given payer). Related administration procedure Use most appropriate revenue code for cost center where services were performed (eg, 0510, clinic). PAGEOF AVER NAME	t by Med sepa re Rela Use 0 9637 (spec HEALTH PLAN ID 59 R.REL 60 INSURED'S U 64 DOCUM	dicare hospita arately payabl ugh the 340E ated admini CPT® code rep 72, therapeut cify substance REATION DA SAREA	e drugs (includie e drugs (includie program. ¹¹ stration proce c, prophylactic, or drug); subcu	ms to bill fung NEUPOO edure perfo or diagnost taneous or TOTALS 55 EST. AMOU S5 EST. AMOU NOUP NAME	or certain GEN®) acqu rmed, such tic injection intramuscu unr DUE	as Jlar 56 NPI 57 07HER PRV ID 62 INSURANCE O 62 INSURANCE O 63 INSURANCE O 64 INSURANCE O 65 INSURA	68 73 JAL		
general pharmacy (or 0636, if required a given payer). Related administration procedure Use most appropriate revenue code for cost center where services were performed (eg, 0510, clinic). PAGEOF VER NAMEOF NUERD'S NAMEOF TIAGNOSIS CODES (BOX 67) Enter appropriate ICD-10-CM diagnosis code(s) corresponding to patient's diagnosis. Allowable diagnosis codes may vary by payer. KXX A B CODEA PRINCIPAL PROCEDURE A CODEA CODEA CODEA CODEA A PRINCIPAL PROCEDURE A 	HEALTH PLAN ID	dicare hospita arately payabl ugh the 340E ated admini CPT® code reg 72, therapeuti cify substance CREATION DA BREEL SAC BREEL SAC BRE	I outpatient clai e drugs (includie program. ¹¹ stration proce c, prophylactic, or drug); subcu	ms to bill fung NEUPOO	or certain GEN®) acqu rmed, such tic injection intramuscu unt DUE	as	68 73 JAL		
general pharmacy (or 0636, if required a given payer). Related administration procedure Use most appropriate revenue code for cost center where services were performed (eg, 0510, clinic). PAGE OF VER NAME DIAGNOSIS CODES (BOX 67) Enter appropriate ICD-10-CM diagnosis code(s) corresponding to patient's diagnosis. Allowable diagnosis codes may vary by payer. MUT	Health PLAN ID	dicare hospita arately payabl ugh the 340E ated admini CPT® code rep 72, therapeuti cify substance CREATION DA BER BER BER BER BER BER BER BER BER BE	I outpatient clai e drugs (includie program. ¹¹ stration proce c, prophylactic, or drug); subcu	ms to bill fing NEUPOO	or certain GEN®) acqu rmed, such tic injection intramuscu intramuscu intramuscu ses employer NAM	as	68 73 IAL F		
general pharmacy (or 0636, if required a given payer). Related administration procedure Use most appropriate revenue code for cost center where services were performed (eg, 0510, clinic). PAGEOF AVER NAME DIAGNOSIS CODES (BOX 67) Enter appropriate ICD-10-CM diagnosis code(s) corresponding to patient's diagnosis. Allowable diagnosis codes may vary by payer. KXX X A B CODE PRINCIPAL PROCEDURE CODE CODE CODE CODE CODE CODE CODE CODE REASONDX CODE C	Health PLAN ID	dicare hospita arately payabl ugh the 340E ated admini CPT® code reg 72, therapeuti cify substance CREATION DA BREEL SAC BREEL SAC BRE	e drugs (includie e drugs (includie program. ¹¹ stration proce c, prophylactic, or drug); subcu	ms to bill fing NEUPOO	or certain GEN®) acqu rmed, such tic injection intramuscu unt DUE	aS Jar 56 NPI 57 0THER PRV ID 62 INSURANCE O 62 INSURANCE O 63 INSURANCE O 64 INSURANCE O 64 INSURANCE O 65 INSURANCE O 66 INSURANCE O 67 INSURANCE O 68 INSURANCE O 69 INSURANCE O 69 INSURANCE O 60 INSURAN	68 73 IAL F		
general pharmacy (or 0636, if required a given payer). Related administration procedure Use most appropriate revenue code for cost center where services were performed (eg, 0510, clinic). PAGEOF PAGE _	ti by Med sepa re Med sepa throu Rela Use (9637 (spec (spec 59 P.Rel, 60 INSURED'S U 59 P.Rel, 60 INSURED'S U 64 DOCUM 64 DOCUM 64 DOCUM 64 DOCUM	dicare hospita arately payabl ugh the 340E ated admini CPT® code reg 72, therapeuti cify substance CREATION DA BREEL SAC BREEL SAC BRE	e drugs (includie e drugs (includie program. ¹¹ stration proce c, prophylactic, or drug); subcu	ms to bill fing NEUPOO	or certain GEN®) acqu rmed, such tic injection intramuscu UNT DUE	aS Jar 56 NPI 57 0THER PRV ID 62 INSURANCE O 62 INSURANCE O 63 INSURANCE O 64 INSURANCE O 64 INSURANCE O 65 INSURANCE O 66 INSURANCE O 67 INSURANCE O 68 INSURANCE O 69 INSURANCE O 69 INSURANCE O 60 INSURAN	68 73 r r r r r r r r r r		
general pharmacy (or 0636, if required a given payer). Related administration procedure Use most appropriate revenue code for cost center where services were performed (eg, 0510, clinic). PAGEOF PAGEOF PAGEOF PAGEOF INSUBED'S NAME DIAGNOSIS CODES (BOX 67) Enter appropriate ICD-10-CM diagnosis code(s) corresponding to patient's diagnosis. Allowable diagnosis codes may vary by payer. XXX .X A B ADMIT XXX .X A B ADMIT CODE READING CODE CODE CODE CODE CODE CODE CODE CODE READING CODE CODE READING CODE C	ti by Med sepa re Rela Use (9637 (spec 9637) (spec 9637 (spec 9637) (spec)9637) (s	dicare hospita arately payabl ugh the 340E ated admini CPT® code reg 72, therapeuti cify substance CREATION DA BREEL SAC BREEL SAC BRE	I outpatient clai e drugs (includia program. ¹¹ stration proce c, prophylactic, or drug); subcu	ms to bill fing NEUPOO	or certain GEN®) acqu rmed, such tic injection intramuscu UNT DUE	aS Jar 56 NPI 57 57 57 57 57 57 57 5	68 73 r r r r r r r r r r		

This sample form is intended as a reference for coding and billing for product and associated services. It is not intended to be a directive, nor does the use of the recommended codes guarantee reimbursement. Physicians and staff may deem other codes or policies more appropriate. Providers should select the coding options that most accurately reflect their internal system guidelines, payer requirements, practice patterns, and the services rendered. Providers are responsible for ensuring the accuracy and validity of all billing and claims for appropriate reimbursement.



Special Instructions for the On-body Injector (OBI) for Neulasta®

A healthcare provider must fill the on-body injector (OBI) with Neulasta[®] using the co-packaged prefilled syringe and then apply the OBI to the patient's skin (abdomen or back of arm). The back of the arm may only be used if there is a caregiver available to monitor the status of the OBI. Approximately 27 hours after the OBI is applied to the patient's skin, Neulasta[®] will be delivered over approximately 45 minutes. A healthcare provider may initiate administration with the OBI on the same day as the administration of cytotoxic chemotherapy, as long as the OBI delivers Neulasta[®] no less than 24 hours after the administration of cytotoxic chemotherapy.

The prefilled syringe co-packaged in the Neulasta[®] Onpro[®] kit contains additional solution to compensate for liquid loss during delivery through the OBI. If this syringe is used for manual subcutaneous injection, the patient will receive an overdose. If the prefilled syringe for manual use is used with the OBI, the patient may receive less than the recommended dose.

Do not use the OBI to deliver any other drug product except the Neulasta[®] prefilled syringe co-packaged with the OBI. Use of the OBI has not been studied in pediatric patients.

The OBI should be applied to intact, non-irritated skin on the arm or abdomen.

A missed dose could occur due to an OBI failure or leakage. Instruct patients using the OBI to notify their healthcare professional immediately in order to determine the need for a replacement dose of pegfilgrastim if they suspect that the device may not have performed as intended. If the patient misses a dose, a new dose should be administered by single prefilled syringe for manual use as soon as possible after detection.

Review the Patient Information and Patient Instructions for Use with the patient and provide the instructions to the patient. Refer to the Healthcare Provider Instructions for Use for the OBI for full administration information.

For any OBI problems, call Amgen at **1-800-772-6436** or **1-844-MYNEULASTA (1-844-696-3852)**.

Indication and Important Safety Information for Neulasta® (pegfilgrastim) and NEUPOGEN® (filgrastim)

Indication

Neulasta[®] and NEUPOGEN[®] are indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. Neulasta[®] is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.

Important Safety Information

Contraindication

 Neulasta® or NEUPOGEN® are contraindicated in patients with a history of serious allergic reactions to human granulocyte colonystimulating factors (G-CSFs), such as pegfilgrastim or filgrastim

Splenic Rupture

- Splenic rupture, including fatal cases, can occur following the administration of Neulasta® and NEUPOGEN®
- Evaluate for an enlarged or ruptured spleen in patients who report left upper abdominal or shoulder pain

Acute Respiratory Distress Syndrome (ARDS)

- ARDS has occurred in patients receiving Neulasta®and NEUPOGEN®
- Evaluate patients who develop a fever and lung infiltrates or respiratory distress after receiving Neulasta® or NEUPOGEN®
- Discontinue Neulasta[®] or NEUPOGEN[®] in patients with ARDS

Serious Allergic Reactions

- Serious allergic reactions, including anaphylaxis can occur in patients receiving Neulasta[®] and NEUPOGEN[®]
- Provide symptomatic treatment for allergic reactions
- Majority of events occurred upon initial exposure and can recur within days after discontinuation of initial anti-allergic treatment

 Permanently discontinue Neulasta[®] or NEUPOGEN[®] in patients with serious allergic reactions

Allergies to Acrylics

- On-body Injector for Neulasta[®] uses acrylic adhesives
- Patients who are allergic to acrylic adhesives may have a significant reaction

Use in Patients with Sickle Cell Disorders

 In patients with sickle cell trait or disease, sickle cell crisis, in some cases fatal, can occur in patients receiving Neulasta[®] and NEUPOGEN[®]. Discontinue if sickle cell crisis occurs.

Glomerulonephritis

- Has occurred in patients receiving NEUPOGEN[®] and Neulasta[®]
- Diagnoses based on azotemia, hematuria, proteinuria, and renal biopsy
- Generally, events resolved after dose reduction or discontinuation of NEUPOGEN[®] and Neulasta[®]
- If suspected, evaluate for cause and if cause is likely, consider dose-reduction or interruption of Neulasta® or NEUPOGEN®

Capillary Leak Syndrome (CLS)

- CLS has been reported after G-CSF administration, including NEUPOGEN[®] and Neulasta[®]
- Characterized by hypotension, hypoalbuminemia, edema, and hemoconcentration
- Episodes vary in frequency, severity, and may be life-threatening if treatment is delayed
- Patients with symptoms should be closely monitored and receive standard symptomatic treatment, which may include intensive care

Please see additional Important Safety Information on page 11.

Thrombocytopenia

- Thrombocytopenia has been reported in patients who received NEUPOGEN[®] and pegfilgrastim
- Monitor platelet counts

Leukocytosis

- White blood cell counts of \geq 100,000/mm³ have been observed in patients who received NEUPOGEN® and Neulasta®
- Monitor CBCs during Neulasta[®] therapy and at least twice weekly for NEUPOGEN[®]
- Adjust NEUPOGEN[®] dosing as clinically indicated to help mitigate risk of leukocytosis
- Dosages of NEUPOGEN[®] that increase the absolute neutrophil count (ANC) beyond 10,000/mm³ may not result in any additional clinical benefit
- Discontinuation of NEUPOGEN[®] therapy usually resulted in a 50% decrease in circulating neutrophils within 1 to 2 days, with a return to pretreatment levels in 1 to 7 days

Cutaneous Vasculitis

- Moderate or severe cases of cutaneous vasculitis have been reported in patients treated with NEUPOGEN[®]
- Most reports involved patients with severe chronic neutropenia on long-term NEUPOGEN[®] therapy
- Hold NEUPOGEN[®] therapy in patients with cutaneous vasculitis
- NEUPOGEN[®] dose may be reduced when the symptoms resolve and ANC has decreased

Potential Effect on Malignant Cells

- G-CSF receptor has been found on tumor cell lines
- The possibility that NEUPOGEN[®] or Neulasta[®] acts as a growth factor for any tumor type, including myeloid malignancies and myelodysplasia, cannot be excluded

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Patients with Severe Chronic Neutropenia

- Confirm the diagnosis of SCN before initiating NEUPOGEN[®] therapy
- MDS and AML have been reported to occur in the natural history of congenital neutropenia without cytokine therapy
- Cytogenetic abnormalities, transformation to MDS, and AML have also been observed in patients treated with NEUPOGEN® for SCN
- Based on available data including a postmarketing surveillance study, the risk of developing MDS and AML appears to be confined to the subset of patients with congenital neutropenia.
- Abnormal cytogenetics and MDS have been associated with the eventual development of myeloid leukemia
- The effect of NEUPOGEN[®] on the development of abnormal cytogenetics and the effect of continued NEUPOGEN[®] administration in patients with abnormal cytogenetics or MDS are unknown. Monitor patients for signs and symptoms of MDS/AML in these settings.
- If a patient with SCN develops abnormal cytogenetics or myelodysplasia, the risks and benefits of continuing NEUPOGEN[®] should be carefully considered

Patients with Breast and Lung Cancer

• MDS and AML have been associated with the use of NEUPOGEN[®] and Neulasta[®] in conjunction with chemotherapy and/or radiotherapy in patients with breast and lung cancer. Monitor patients for signs and symptoms of MDS/AML in these settings.

Simultaneous Use with Chemotherapy and Radiation Therapy Not Recommended

- Safety and efficacy of NEUPOGEN® given simultaneously with cytotoxic chemotherapy and radiation have not been established
- Do not use NEUPOGEN[®] 24 hours before or after cytotoxic chemotherapy
- Avoid simultaneous use of NEUPOGEN[®] with chemotherapy and radiation

Nuclear Imaging

- Increased hematopoietic activity of the bone marrow has been associated with transient positive bone-imaging changes have been seen in patients taking Neulasta[®] or NEUPOGEN[®].
- Consider when interpreting bone-imaging results

Potential Device Failures

- Missed or partial doses have been reported in patients receiving pegfilgrastim via the on-body injector (OBI) due to the device not performing as intended
- In the event of a missed or partial dose, patients may be at increased risk of events such as neutropenia, febrile neutropenia and/or infection than if the dose had been correctly delivered
- Instruct patients to notify their healthcare professional immediately in order to determine the need for a replacement dose if they suspect that the device may not have performed as intended

Aortitis

- Aortitis has been reported in patients receiving Neulasta[®] and NEUPOGEN[®]. It may occur as early as the first week after start of therapy.
- Manifestations may include generalized signs and symptoms such as fever, abdominal pain, malaise, back pain, and increased inflammatory markers (e.g., c-reactive protein and white blood cell count).
- Consider aortitis in patients who develop these signs and symptoms without known etiology. Discontinue Neulasta[®] and NEUPOGEN[®] if aortitis is suspected.

Most common adverse reactions in patients taking NEUPOGEN®

 Anemia, constipation, diarrhea, oral pain, vomiting, asthenia, malaise, peripheral edema, decreased hemoglobin, decreased appetite, oropharyngeal pain, and alopecia

Most common adverse reactions in patients taking Neulasta®

- Bone pain
- Pain in extremity

 $\mathsf{NEUPOGEN}^{\circledast}$ is administered by subcutaneous injection, short intravenous infusion (15 to 30 minutes), or continuous intravenous infusion.

- Prefilled Syringe: Injection: 300 mcg/0.5 mL in a single-dose prefilled syringe; Injection: 480 mcg/0.8 mL in a single-dose prefilled syringe Neulasta[®] is administered by subcutaneous injection.
- Injection: 6 mg/0.6 mL in a single-dose prefilled syringe for manual use only.
- Injection: 6 mg/0.6 mL in a single-dose prefilled syringe co-packaged with the on-body injector (OBI) for Neulasta[®] (Neulasta[®] Onpro[®] kit).

Please see full <u>Prescribing Information</u> for Neulasta[®] and full <u>Prescribing Information</u> for NEUPOGEN[®].





See How We Can Help Your Patients

Offering the tools, information, and support for Amgen products that make a difference for you and your patients



BENEFIT VERIFICATION

Submit, store, and retrieve benefit verifications for all your patients currently on an Amgen product



AMGEN REIMBURSEMENT SPECIALISTS

Connect with an Amgen Reimbursement Counselor, or schedule a visit with a Field Reimbursement Specialist



AMGEN NURSE NAVIGATORS*

A single point of contact for Amgen Assist 360[™] services, designed to help your patients find the resources⁺ that are most important to them

* Amgen Nurse Navigators are only available to patients that are prescribed certain products. Nurse Navigators are there to support, not replace, your treatment plan and do not provide medical advice or case management services. Patients should always consult their healthcare provider regarding medical decisions or treatment concerns.

[†] Resources include referrals to independent nonprofit patient assistance programs. Eligibility for resources provided by independent nonprofit patient assistance programs is based on the nonprofits' criteria. Amgen has no control over these programs and provides referrals as a courtesy only.

Call 1-888-4ASSIST (888-427-7478) Monday to Friday, 9:00 AM to 8:00 PM EST, or visit www.AmgenAssist360.com

References

1. Neulasta® (peafilgrastim) prescribing information, Amgen, 2. Neulasta® (peafilgrastim) Onpro® kit Healthcare Provider Instructions for Use, Amgen, 3. RED BOOK Online®, Neulasta® (pegfilgrastim) injection Onpro® kit. https://www.micromedexsolutions.com/micromedex2/librarian/CS/62DD04/ND_PR/evidencexpert/ND_P/evidencexpert/ DUPLICATIONSHIELDSYNC/03D81D/ND_PG/evidencexpert/ND_B/evidencexpert/ND_AppProduct/evidencexpert/ND_T/evidencexpert/PFActionId/redbook.ShowProductSearc h Results? SearchTerm = NEULASTA% 200 NPRO & searchType = red book ProductName & searchTerm Id = 44479 & searchContent = REDBOOK & searchFilterAD = filterADActive & searchFilterAD = filterADActive & searchFilterADActive & searcterRepackager=filterExcludeRepackager&searchPattern=%5Eneulasta. Accessed September 23, 2021. 4. RED BOOK Online®. Neulasta® (pegfilgrastim) injection. https://www. micromedexsolutions.com/micromedex2/librarian/CS/F14A98/ND_PR/evidencexpert/ND_P/evidencexpert/DUPLICATIONSHIELDSYNC/63A008/ND_PG/evidencexpert/ND_B/ evidencexpert/ND_AppProduct/evidencexpert/ND_T/evidencexpert/PFActionId/redbook.ShowProductSearchResults?SearchTerm=NEULASTA&searchType=redbookProduct Name&searchTermId=30621&searchContent=REDBOOK&searchFilterAD=filterADActive&searchFilterRepackager=filterExcludeRepackager&searchPattern=%5ENeulasta. Accessed September 23, 2021. 5. Centers for Medicare & Medicaid Services. Healthcare Common Procedure Coding System (HCPCS) Application Summaries and Coding Decisions. https:// www.cms.gov/files/document/2021-hcpcs-application-summary-bi-annual-1-2021-non-drug-and-non-biological-items-and-services.pdf. Accessed November 1, 2021. 6. American Medical Association. Current Procedural Terminology (CPT®) 2021 Professional Edition. American Medical Association. 2020. 7. Value Healthcare Services. Understanding Hospital Revenue Codes. http://valuehealthcareservices.com/education/understanding-hospital-revenue-codes/. Accessed September 12, 2021. 8. Centers for Medicare & Medicaid Services. Medicare Claims Processing Manual - Chapter 25. Completing and Processing the Form CMS-1450 Data Set. Rev 4194. https://www.cms.gov/Regulations-and-Guidance/ Guidance/Manuals/downloads/clm104c25.pdf. Accessed September 12, 2021. 9. Centers for Medicare & Medicaid Services. Medicare Claims Processing Manual - Chapter 17: Drugs and Biologicals. Rev 10329. http://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/downloads/clm104c17.pdf. Accessed September 12, 2021. 10. Centers for Medicare & Medicaid Services. Medicare Program JW Modifier. https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/Downloads/JW-Modifier-FAQs.pdf. Accessed October 6, 2021. 11. Centers for Medicare & Medicaid Services. Medicare-FFS Program. https://www.cms.gov/medicare/medicare-fee-for-servicepayment/hospitaloutpatientpps/downloads/billing-340b-modifiers-under-hospital-opps.pdf. Accessed October 6, 2021. 12. NEUPOGEN® (filgrastim) prescribing information, Amgen.



Amgen One Amgen Center Drive Thousand Oaks, CA 91320-1799 www.amgen.com © 2021 Amgen Inc. All rights reserved. USA-OCF-81826 10/21